#### Contact

Merck KGaA, Darmstadt, Germany Investor Relations Frankfurter Strasse 250 64293 Darmstadt Germany

Phone: +49 6151 72 3321

e-mail: investor.relations@merckgroup.com

www.merckgroup.com

WKN: 659990

ISIN: DE0006599905

Ticker Symbol: MRK

# Financial Statements Q1 2021 - Q4 2022

## Content

#### 1 Income statements

- 1.1 Group, quarterly
- 1.2 Life Science, quarterly
- 1.3 Healthcare, quarterly
- 1.4 Electronics, quarterly
- 1.5 Corporate/Others, quarterly
- 1.6 Financial result, quarterly

### 2 Cash flow statement

3 Balance sheet

Net sales/Net sales growth	by business sector	Merck KGa	A, Darmst		any <sup>1</sup>												_																
€ million	Q1	Q2	H1	<b>2021</b> Q3	9М	Q4	H2	FY	Q1	Q2	H1	<b>2022</b> Q3	9М	Q4	H2	FY		Q1	Q2	H1	<b>2021</b> Q3	9M	Q4	H2	FY	Q1	Q2	H1	<b>2022</b> Q3	2 9M	Q4	H2	FY
Group YoY $\Delta$ Acquisitions $\Delta$ Fx $\Delta$	<b>4,630.7</b> 261.0 -19.6 -251.9	<b>4,870.2</b> 751.1 -0.5 -196.5	9,500.9 1,012.1 -20.1 -448.4	<b>4,972.7</b> 525.6 -1.5 43.0	14,473.6 1,537.7 -21.6 -405.5	<b>5,213.0</b> 614.5 0.8 156.9	10,185.7 1,140.1 -0.7 199.9	19,686.6 2,152.2 -20.8 -248.5	5,197.8 567.1 5.0 203.2	5,568.4 698.2 25.1 351.8	10,766.2 1,265.3 30.1 555.0	5,805.7 833.0 28.8 448.9	16,571.9 2,098.3 58.9 1,003.9	5,660.4 447.3 16.7 204.5	11,466.1 1,280.3 45.5 653.4	22,232.3 2,545.7 75.6 1,208.4	Group YoY % Acquisitions % Fx %	6.0% -0.4% -5.8%	18.2% 0.0% -4.8%	11.9% -0.2% -5.3%	11.8% 0.0% 1.0%	-0.2%	0.0%		-0.1%	12.2% 0.1% 4.4%	0.5%	0.3%	16.8% 0.6% 9.0%	0.4%	8.6% 0.3% 3.9%	12.6% 0.4% 6.4%	0.4%
Organic ∆	532.5	948.1	1,480.6	484.1	1,964.7	456.8	940.9	2,421.5	358.9	321.2	680.2	355.3	1,035.5	226.2	581.5	1,261.7	Organic %	12.2%		17.4%				10.4%				7.2%				5.7%	
Life Science YoY A	<b>2,131.1</b> 361.7	418.8	<b>4,356.6</b> 780.5	<b>2,248.8</b> 338.6	<b>6,605.4</b> 1,119.1	<b>2,386.4</b> 356.0	<b>4,635.2</b> 694.6	<b>8,991.8</b> 1,475.1	<b>2,445.4</b> 314.3	<b>2,647.8</b> 422.3	<b>5,093.2</b> 736.6	<b>2,680.7</b> 431.9	<b>7,773.9</b> 1,168.5	<b>2,606.4</b> 220.1	651.9	<b>10,380.3</b> 1,388.6	Life Science YoY %	20.4%					17.5%		19.6%					17.7%		14.1%	
Acquisitions Δ Fx Δ	0.1 -110.5	0.2 -91.0	0.3 -201.5	0.3 10.9	0.6 -190.6	0.8 67.0	1.1 78.0	1.4 -123.6	5.0 102.0	25.1 164.6	30.1 266.6	28.8 206.6	58.9 473.2	16.7 102.7	45.5 309.3	75.6 575.9	Acquisitions % Fx %	0.0% -6.2%	0.0% -5.0%	0.0% -5.6%	0.0%	0.0% -3.5%		0.0% 2.0%	0.0%		1.1% 7.4%		1.3% 9.2%		0.7% 4.3%	1.0% 6.7%	
Organic Δ	472.1	509.7	981.8	327.3	1,309.1	288.3	615.6	1,597.4	207.4	232.5	439.9	196.5	636.4	100.7	297.2	737.1	Organic %	26.7%		27.5%							10.4%						
Healthcare YoY Δ Acquisitions Δ	<b>1,638.9</b> -61.6 -19.7	1,787.7 288.5 -0.6	3,426.7 226.9 -20.3	1,787.6 86.1 -1.8	<b>5,214.2</b> 313.0 -22.1	1,874.6 136.6 0.0	3,662.2 222.7 -1.8	<b>7,088.9</b> 449.6 -22.1	<b>1,795.0</b> 156.0 0.0	<b>1,924.2</b> 136.4 0.0	<b>3,719.1</b> 292.5 0.0	2,089.3 301.7 0.0	<b>5,808.5</b> 594.2 0.0	<b>2,030.3</b> 155.6 0.0	<b>4,119.6</b> 457.4 0.0	<b>7,838.7</b> 749.9 0.0	Healthcare YoY % Acquisitions %	-3.6% -1.2%	19.2% 0.0%		5.1% -0.1%	6.4%		6.5% -0.1%	6.8%	9.5% 0.0%	7.6% 0.0%	8.5% 0.0%	16.9% 0.0%	11.4%	8.3% 0.0%	12.5% 0.0%	
FxΔ	-100.8	-65.1	-165.9	17.4	-148.4	54.9	72.3	-93.5	49.3	110.8	160.1	146.5	306.6	52.7	199.2	359.3	Fx %	-5.9%	-4.3%	-5.2%	1.0%	-3.0%	3.2%	2.1%	-1.4%	3.0%	6.2%	4.7%	8.2%	5.9%	2.8%	5.4%	5.1%
Organic Δ  Electronics	58.9 <b>860.7</b>	354.2 856.9	413.1 1.717.6	70.4 936.3	483.5 2.653.9	81.8 952.0	152.2 1,888.3	565.3 3.605.9	106.8 957.4	25.6 996.4	132.4 1,953.9	155.3 1.035.7	287.6 2.989.5	102.9 1,023.7	258.2 2.059.3	390.5 4.013.2	Organic % Electronics	3.5%	23.6%	12.9%	4.1%	9.9%	4.7%	4.4%	8.5%	6.5%	1.4%	3.9%	8.7%	5.5%	5.5%	7.0%	5.5%
YoY ∆ Acquisitions ∆	-39.1 0.0	43.8	4.6 0.0	101.0	105.6	121.8 0.0	222.8	227.4	96.8 0.0	139.5 0.0	236.2	99.4 0.0	335.6 0.0	71.6 0.0	171.0 0.0	407.2	YoY % Acquisitions %	-4.3% 0.0%	5.4% 0.0%	0.3% 0.0%	12.1% 0.0%	4.1% 0.0%	14.7% 0.0%	13.4% 0.0%	6.7% 0.0%	11.2% 0.0%	16.3% 0.0%	13.8% 0.0%	10.6% 0.0%	12.6% 0.0%	7.5% 0.0%	9.1% 0.0%	
Fx Δ Organic Δ	-40.6 1.5	-40.4 84.2	-81.0 85.7	14.6 86.3	-66.4 172.0	35.0 86.8	49.6 173.1	-31.4 258.8	51.9 44.8	76.3 63.1	128.3 107.9	95.8 3.6	224.1 111.5	49.1 22.6	144.9 26.1	273.2 134.1	Fx % Organic %	-4.5% 0.2%	-5.0%		1.7%			3.0%				7.5%		8.4% 4.2%		7.7% 1.4%	
EBITDA pre by business s	ector Merck KGaA, D		Germany <sup>1</sup>	<b>2021</b> Q3	9M	Q4	H2	FY	Q1	Q2	H1	<b>2022</b> Q3	9M	Q4	H2	FY	€ million	Q1	Q2	H1	<b>2021</b> Q3	9М	Q4	H2	FY	Q1	Q2	H1	<b>2022</b> Q3		Q4	H2	FY
Group	1,510,6	1.576.2	3.086.8	1.551.9	4.638.8	1,464.2	3,016.1	6.102.9	1.628.8	1.782.0	3,410,8	1.810.5	5.221.2	1.627.9	3.438.4	6.849.1	Group																
% Margin	32.6%	32.4%	32.5%	31.2%	32.0%	28.1%	29.6%	31.0%	31.3%	32.0%	31.7%	31.2%	31.5%	28.8%	30.0%	30.8%																	
YoY Δ Acquisitions Δ	329.3 -1.5	502.0 -0.7	831.3 -2.2	-148.8 -1.4	682.5 -3.6	219.0 -1.7	70.2 -3.1	901.5 -5.3	118.1 -3.3	205.8 5.3	323.9 2.1	258.5 7.1	582.5 9.2	163.7 -27.9	422.3 -20.8	746.2 -18.7	YoY % Acquisitions %	27.9% -0.1%	46.7% -0.1%		-8.7% -0.1%	17.3% -0.1%			17.3% -0.1%		13.1%					14.0% -0.7%	
FxΔ	-98.6	-55.4	-154.0	38.0	-116.0	83.4	121.5	-32.6	96.9	150.0	246.9	135.8	382.7	9.3	145.1	392.0	Fx %	-8.3%	-5.2%	-6.8%	2.2%	-2.9%	6.7%	4.1%	-0.6%	6.4%	9.5%	8.0%	8.8%	8.3%	0.6%	4.8%	6.4%
Organic ∆ Life Science	429.3 <b>793.6</b>	558.2 829.1	987.5 <b>1,622.7</b>	-185.4 <b>823.6</b>	802.1 2.446.4	137.3 840.2	-48.1 1,663.8	939.4 3,286.6	24.5 927.1	50.5 1,005.7	75.0 1,932.8	115.6 976.4	190.6 2,909.2	182.4 850.3	298.0 1,826.8	373.0 3,759.6	Organic % Life Science	36.3%	52.0%	43.8%	-10.9%	20.3%	11.0%	-1.6%	18.1%	1.6%	3.2%	2.4%	7.5%	4.1%	12.5%	9.9%	6.1%
% Margin	37.2%	37.3%	37.2%	36.6%	37.0%	35.2%	35.9%	36.6%	37.9%	38.0%	37.9%	36.4%	37.4%	32.6%	34.6%	36.2%																	
YoY ∆ Acquisitions ∆	240.5 -0.5	259.9 -0.6	500.4 -1.0	193.4 -1.2	693.8 -2.2	187.1 -1.6	380.5 -2.7	880.9 -3.8	133.5 -3.3	176.6 5.3	310.1 2.1	152.8 7.1	462.9 9.2	10.1 -22.2	162.9 -15.1	473.0 -13.1	YoY % Acquisitions %	43.5% -0.1%	45.7% -0.1%		30.7% -0.2%	39.6% -0.1%			36.6%	16.8% -0.4%	21.3% 0.6%		18.6% 0.9%	18.9% 0.4%		9.8%	
FxΔ	-34.6		-55.8	10.3	-45.6	22.8	33.1	-22.7	43.4	51.3	94.8	56.7	151.5	14.3	71.0	165.8	Fx %	-6.3%	-3.7%			-2.6%	3.5%	2.6%	-0.9%	5.5%	6.2%					4.3%	
Organic Δ  Healthcare	275.6 <b>532.9</b>	281.7 581.0	557.3 1.113.9	184.3 <b>540.8</b>	741.6 <b>1.654.7</b>	165.8 498.4	350.1 1.039.2	907.4 2.153.1	93.3 <b>529.1</b>	119.9 <b>603.6</b>	213.2 1.132.7	89.0 <b>710.9</b>	302.2 1.843.5	18.1 <b>633.1</b>	107.1 1.343.9	320.3 2.476.6	Organic % Healthcare	49.9%	49.5%	49.7%	29.2%	42.3%	25.4%	27.3%	37.7%	11.8%	14.5%	13.1%	10.8%	12.4%	2.2%	6.4%	9.7%
% Margin	32.5%		32.5%	30.3%	31.7%	26.6%	28.4%	30.4%	29.5%	31.4%	30.5%	34.0%	31.7%	31.2%	32.6%	31.6%																	
YoY ∆ Acquisitions ∆	60.8 -1.4	206.9 -0.2	267.7 -1.5	-355.2 -0.2	-87.5 -1.7	-26.7 -0.2	-381.9 -0.4	-114.1 -1.9	-3.8 0.0	22.6 0.0	18.8 0.0	170.1 0.0	188.8 0.0	134.6 0.0	304.7 0.0	323.5 0.0	YoY % Acquisitions %	12.9% -0.3%	55.3% 0.0%		-39.6% 0.0%		-5.1% · 0.0%		-5.0% -0.1%		3.9%			11.4%	0.0%	0.0%	
FxΔ	-74.6		-130.3	21.1	-109.2	36.2	57.3	-73.0	35.6	78.1	113.7	110.4	224.1	27.5	137.9	251.5	Fx %	-15.8%		-15.4%				4.0%	-3.2%				20.4%			13.3%	
Organic Δ  Electronics	136.8 273.4	262.7 257.9	399.5 <b>531.3</b>	-376.1 <b>296.7</b>	23.4 828.0	-62.7 <b>299.7</b>	-438.8 <b>596.5</b>	-39.3 1.127.8	-39.4 289.3	-55.5 <b>293.1</b>	-94.9 582.4	59.7 <b>301.6</b>	-35.2 884.0	107.1 308.2	166.8 <b>609.8</b>	71.9 1.192.2	Organic % Electronics	29.0%	70.2%	47.2%	-42.0%	1.3% -	11.9%	-30.9%	-1.7%	-7.4%	-9.5%	-8.5%	11.0%	-2.1%	21.5%	16.1%	3.3%
% Margin	31.8%	30.1%	30.9%	31.7%	31.2%	31.5%	31.6%	31.3%	30.2%	29.4%	29.8%	29.1%	29.6%	30.1%	29.6%	29.7%																	
YoY Δ Acquisitions Δ	-11.7 0.0	19.8 0.0	8.1 0.0	42.6 0.0	50.6 0.0	53.6 0.0	96.2 0.0	104.3 0.0	15.9 0.0	35.2 0.0	51.1 0.0	4.9 0.0	56.0 0.0	8.4 0.0	13.3	64.4	YoY % Acquisitions %	-4.1% 0.0%	8.3% 0.0%	1.5% 0.0%	16.8%	6.5% 0.0%	21.8%	19.2%	10.2%	5.8%	13.7%	9.6% 0.0%	1.6% 0.0%	6.8%	2.8%	2.2% 0.0%	
FxΔ	-18.7	-14.2	-32.9	13.7	-19.2	23.8	37.5	4.6	32.4	40.0	72.4	48.9	121.3	25.8	74.7	147.1	Fx %	-6.5%	-6.0%	-6.3%	5.4%	-2.5%	9.7%	7.5%	0.5%	11.9%	15.5%	13.6%	16.5%	14.6%	8.6%	12.5%	13.0%
Organic Δ Corporate/Others	7.0 -89.3	34.0 -91.8	40.9 -181.1	28.9 -109.3	69.8 -290.4	29.8 -174.2	58.7 -283.4	99.6 -464.5	-16.5 -116.8	-4.8 -120.3	-21.3 -237.1	-44.0 -178.4	-65.3 -415.5	-17.3 -163.7	-61.4 -342.0	-82.7 - <b>579.2</b>	Organic % Corporate/Others	2.4%	14.3%	7.8%	11.4%	9.0%	12.1%	11.7%	9.7%	-6.0%	-1.9%	-4.0% -	-14.8%	-7.9%	-5.8% -	10.3%	-7.3%
YoY A	39.7		55.1	-29.6	25.5	5.0	-24.6	30.5		-28.6	-56.0	-69.1	-125.2	10.5	-58.6	-114.6	YoY %	-30.8%	-14.4%	-23.3%	37.1%	-8.1%	-2.8%	9.5%	-6.2%	30.7%	31.1%	30.9%	63.3%	43.1%	-6.0%	20.7%	24.7%

Due to rounding the sum of individual values may not add up to totals presented

1 Prior-year figures have been adjusted due to product reallocations between the Life Science and Electronics business sectors, prior year growth figures do not reflect these shifts.

Income Statement	Merck KGaA,	Darmstadt,	Germany <sup>1</sup>
------------------	-------------	------------	----------------------

Group € million	Q1	Q2	H1	<b>2</b> 0 Q3	0 <b>21</b> 9M	Q4	H2	FY	Q1	02	H1	<b>20</b> 2 Q3	22 9M	Q4	H2	FY	Q1	Q2	H1	Change Q3	YoY gml	Q4	H2	FY
e minion	QI	QZ	- 111	વડ	SIVI	Q4 <sub>1</sub>	ΠZ	FI	QI	QZ	111	હડ		Q4	П		QI	QZ	- 111	હડ	SIVI	Q4	112	
Net sales	,	4,870.2	9,500.9		14,473.6		10,185.7		•	5,568.4	10,766.2	5,805.7	16,571.9	-,	11,466.1	22,232.3	12.2%	14.3%	13.3%	16.8%	14.5%	8.6%	12.6%	12.9%
Cost of sales	,	-1,813.0	-3,533.5	-1,858.8	-5,392.4	-1,958.8	-3,817.7	-7,351.2		-2,108.6	,	-2,147.5	-6,243.1	-2,284.2	-4,431.6	-8,527.3	15.5%	16.3%	15.9%	15.5%	15.8%	16.6%	16.1%	16.0%
thereof amortization of intangible assets	-53.9	-49.0	-102.9	-50.9	-153.8	-47.6	-98.5	-201.5	-50.3	-53.2	-103.6	-52.3	-155.9	-51.3	-103.6	-207.1	-6.7%	8.6%	0.6%	2.8%	1.3%	7.6%	5.1%	2.8%
Gross profit	,	3,057.2	5,967.3	3,113.9	9,081.2	3,254.2	6,368.1	12,335.4	3,210.8	3,459.8	6,670.5	3,658.2	10,328.8	3,376.2	7,034.4	13,705.0	10.3%	13.2%	11.8%	17.5%	13.7%	3.7%	10.5%	11.1%
in % of net sales	62.8%	62.8%	62.8%	62.6%	62.7%	62.4%	62.5%	62.7%	61.8%	62.1%	62.0%	63.0%	62.3%	59.6%	61.4%	61.6%								
SG&A		-1,416.8	-2,707.5	-1,399.9	-4,107.5	-1,623.6	-3,023.5	-5,731.0	-1,451.8	-1,683.1		-1,782.4	-4,917.3	-1,793.0	-3,575.3	-6,710.3	12.5%	18.8%	15.8%	27.3%	19.7%	10.4%	18.2%	17.1%
in % of net sales	27.9%	29.1%	28.5%	28.2%	28.4%	31.1%	29.7%	29.1%	27.9%	30.2%	29.1%	30.7%	29.7%	31.7%	31.2%	30.2%								
Marketing and selling expenses	-1,007.3	-1,035.4	-2,042.7	-1,066.3	-3,109.0	-1,194.7	-2,261.0	-4,303.7	-1,087.2	-1,193.6		-1,223.5	-3,504.3	-1,209.4	-2,432.9	-4,713.7	7.9%	15.3%	11.7%	14.7%	12.7%	1.2%	7.6%	9.5%
thereof amortization of intangible assets (M&S)	-145.9	-145.7	-291.6	-144.7	-436.4	-152.3	-297.1	-588.7	-144.8	-153.7	-298.5	-159.9	-458.4	-158.1	-317.9	-616.4	-0.8%	5.5%	2.3%	10.5%	5.0%	3.8%	7.0%	4.7%
Administration expenses	-270.8	-301.1	-572.0	-304.9	-876.9	-350.3	-655.2	-1,227.2	-287.2	-330.5	-617.7	-327.9	-945.7	-360.8	-688.7	-1,306.4	6.0%	9.8%	8.0%	7.5%	7.8%	3.0%	5.1%	6.5%
Impairment losses and reversals (IFRS 9)	-6.0	-0.1	-6.0	0.7	-5.3	6.7	7.4	1.4	-5.0	-8.7	-13.6	6.2	-7.4	1.9	8.1	-5.5	-16.5%		126.6%	767.1%	39.8%	-72.1%	9.1%	n.m.
Other operating expenses/income	-6.6	-80.2	-86.8	-29.5	-116.2	-85.3	-114.8	-201.5	-72.4	-150.4	-222.8	-237.2	-460.0	-224.6	-461.8	-684.6	>1.000%	87.6%	156.8%	705.2%		100.070	302.4%	239.7%
Impairments**	-3.2	-7.8	-11.0	-18.9	-29.9	-22.8	-41.7	-52.7	-2.6	-90.0	-92.6	-10.9	-103.5	-128.4	-139.3	-231.9	-17.5%		740.7%		246.4%		234.0%	339.9%
Research and development costs	-576.3	-591.1	-1,167.3	-666.5	-1,833.9	-591.9	-1,258.4	-2,425.7	-585.5	-599.6	-1,185.1	-641.7	-1,826.8	-693.7	-1,335.4	-2,520.5	1.6%	1.4%	1.5%	-3.7%	-0.4%	17.2%	6.1%	3.9%
in % of net sales	12.4%	12.1%	12.3%	13.4%	12.7%	11.4%	12.4%	12.3%	11.3%	10.8%	11.0%	11.1%	11.0%	12.3%	11.6%	11.3%								
thereof amortization of intangible assets (R&D)	-3.0	-4.1	-7.1	-3.3	-10.4	-2.7	-6.0	-13.1	-1.7	-1.7	-3.4	-1.6	-5.0	-1.7	-3.3	-6.7	-44.2%	-58.4%	-52.5%	-51.4%	-52.1%	-37.8%	-45.2%	-49.1%
EBIT	1,043.1	1,049.3	2,092.5	1,047.4	3,139.8	1,038.7	2,086.1	4,178.6	1,173.4	1,177.0	2,350.4	1,234.2	3,584.6	889.6	2,123.7	4,474.2	12.5%	12.2%	12.3%	17.8%	14.2%	-14.4%	1.8%	7.1%
in % of net sales	22.5%	21.5%	22.0%	21.1%	21.7%	19.9%	20.5%	21.2%	22.6%	21.1%	21.8%	21.3%	21.6%	15.7%	18.5%	20.1%								
Depreciation and amortization	423.7	422.3	846.1	447.4	1,293.5	474.0	921.4	1,767.5	429.6	532.3	961.9	469.7	1,431.6	598.5	1,068.2	2,030.1	1.4%	26.0%	13.7%	5.0%	10.7%	26.3%	15.9%	14.9%
EBITDA	1,466.9	1,471.6	2,938.5	1,494.8	4,433.4	1,512.7	3,007.5	5,946.1	1,603.0	1,709.4	3,312.3	1,703.9	5,016.2	1,488.1	3,191.9	6,504.3	9.3%	16.2%	12.7%	14.0%	13.1%	-1.6%	6.1%	9.4%
in % of net sales	31.7%	30.2%	30.9%	30.1%	30.6%	29.0%	29.5%	30.2%	30.8%	30.7%	30.8%	29.3%	30.3%	26.3%	27.8%	29.3%								
EBITDA pre	1,510.6	1,576.2	3,086.8	1,551.9	4,638.7	1,464.2	3,016.1	6,102.9	1,628.8	1,782.0	3,410.8	1,810.5	5,221.2	1,627.9	3,438.4	6,849.1	7.8%	13.1%	10.5%	16.7%	12.6%	11.2%	14.0%	12.2%
in % of net sales	32.6%	32.4%	32.5%	31.2%	32.0%	28.1%	29.6%	31.0%	31.3%	32.0%	31.7%	31.2%	31.5%	28.8%	30.0%	30.8%	** ***		44.00/	40.00/	24.40/	7.00/	2 40/	26 70/
Financial result	-59.1	-94.8	-153.9	-54.2	-208.0	-46.8	-101.0	-254.9	-34.3	-55.1	-89.4	-47.0	-136.4	-50.5	-97.5	-186.9	-41.9%	-41.9%	-41.9%	-13.2%	-34.4%	7.8%	-3.4%	-26.7%
Profit before income tax from continuing operations	984.1	954.6	1,938.6	993.2	2,931.8	991.9	1,985.1	3,923.7	1,139.1	1,122.0	2,261.0	1,187.2	3,448.2	839.1	2,026.2	4,287.3	15.8%	17.5%	16.6%	19.5%	17.6%	-15.4%	2.1%	9.3%
Income tax	-236.2	-207.8	-443.9	-229.4	-673.3	-185.4	-414.8	-858.7	-255.4	-251.7	-507.1	-261.2	-768.3	-179.7	-440.9	-948.0	8.1%	21.1%	14.2%	13.8%	14.1%	-3.0%	6.3%	10.4%
Income tax rate	24.0%	21.8%	22.9%	23.1%	23.0%	18.7%	20.9%	21.9%	22.4%	22.4%	22.4%	22.0%	22.3%	21.4%	21.8%	22.1%								
Profit after tax from continuing operations	747.9	746.8	1,494.7	763.8	2,258.5	806.6	1,570.4	3,065.0	883.7	870.2	1,754.0	926.0	2,679.9	659.3	1,585.3	3,339.3	18.2%	16.5%	17.3%	21.2%	18.7%	-18.3%	1.0%	8.9%
Profit after tax from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Profit after tax	747.9	746.8	1,494.7	763.8	2,258.5	806.6	1,570.4	3,065.0	883.7	870.2	1,754.0	926.0	2,679.9	659.3	1,585.3	3,339.3	18.2%	16.5%	17.3%	21.2%	18.7%	-18.3%	1.0%	8.9%
of which: attributable to Merck KGaA shareholders (n	746.6	745.2	1,491.8	760.8	2,252.5	802.1	1,562.9	3,054.7	880.4	867.1	1,747.5	923.2	2,670.7	655.0	1,578.1	3,325.7	17.9%	16.4%	17.1%	21.3%	18.6%	-18.3%	1.0%	8.9%
of which: attributable to non-controlling interests	1.3	1.6	2.9	3.0	5.9	4.4	7.5	10.4	3.3	3.1	6.4	2.8	9.2	4.4	7.2	13.6	152.1%	95.2%	120.9%	-7.4%	55.4%	-1.5%	-3.9%	31.1%
EPS in €	1.72	1.71	3.43	1.75	5.18	1.84	3.59	7.03	2.02	1.99	4.02	2.12	6.14	1.51	3.63	7.65	17.4%	16.4%	17.2%	21.1%	18.5%	-17.9%	1.1%	8.8%
thereof from continuing operations	1.72	1.71	3.43	1.75	5.18	1.84	3.59	7.03	2.02	1.99	4.02	2.12	6.14	1.51	3.63	7.65	17.4%	16.4%	17.2%	21.1%	18.5%	-17.9%	1.1%	8.8%
thereof from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
ancidor moni discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00								
EPS pre in €*	2.18	2.24	4.42	2.24	6.66	2.06	4.30	8.72	2.41	2.64	5.05	2.68	7.73	2.32	5.01	10.05	10.6%	17.9%	14.3%	19.6%	16.1%	12.6%	16.5%	15.3%
Number of theoretical shares in million	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8								
Reconciliation to EBITDA pre																								
EBITDA	1,466.9	1,471.6	2,938.5	1,494.8	4,433.4	1,512.7	3,007.5	5,946.1	1,603.0	1,709.4	3,312.3	1703.9	5,016.2	1,488.1	3,191.9	6,504.3	9.3%	16.2%	12.7%	14.0%	13.1%	-1.6%	6.1%	9.4%
Adjustments																								
thereof: Cost of Sales	4.4	7.5	11.9	8.8	20.7	4.5	13.3	25.2	1.6	7.8	9.4	6.0	15.4	16.2	22.2	31.6	-64.3%	4.6%	-20.9%	-31.8%	-25.6%	260.8%	67.0%	25.5%
thereof: Marketing and selling expenses	6.4	2.9	9.2	4.0	13.2	3.9	7.9	17.1	0.5	14.0	14.6	6.4	21.0	11.3	17.7	32.3	-91.3%	385.0%	57.8%	61.0%	58.7%	187.9%	124.0%	88.3%
thereof: Administration expenses	20.4	20.1	40.5	29.4	69.9	13.1	42.5	83.0	19.6	29.7	49.3	31.4	80.7	34.4	65.7	115.1	-3.9%	47.8%	21.7%	6.8%	15.4%	162.9%	54.8%	38.7%
thereof: Other operating expenses/income	10.8	73.1	83.9	14.8	98.7	-75.0	-60.1	23.8	3.0	14.8	17.7	40.7	58.5	33.0	73.7	91.4	-72.6%	-79.8%	-78.9%	174.4%	-40.8%	n.m.	n.m.	284.9%
thereof: Research and development	1.7	1.0	2.7	0.1	2.8	5.0	5.1	7.8	1.1	6.3	7.4	22.1	29.5	45.0	67.1	74.5	-38.7%	518.2%	168.7%	>1.000%	>1.000%	801.8%	>1.000%	850.4%
Total	43.7	104.6	148.3	57.1	205.4	-48.5	8.6	156.9	25.8	72.6	98.4	106.6	205.0	139.8	246.4	344.9	-41.0%	-30.5%	-33.6%	86.7%	-0.2%	n.m.	>1.000%	119.8%
EBITDA pre	1,510.6	1,576.2	3,086.8	1,551.9	4,638.7	1,464.2	3,016.1	6,102.9	1,628.8	1,782.0	3,410.8	1810.5	5,221.2	1,627.9	3,438.4	6,849.1	7.8%	13.1%	10.5%	16.7%	12.6%	11.2%	14.0%	12.2%
														-										

Due to rounding the sum of individual values may not add up to totals presented. 
\*For continuing operations.

\*\* Only reflects impairments classified as adjustments.

<sup>&</sup>lt;sup>1</sup> Prior-year figures are adjusted due to realignment within Coporate and Other.

Reconciliation to EBITDA, EBITDA pre and EPS pre																								
Group				202								2022								Change Q3	e YoY			
€ million	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9М	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
a) Reconciliation to EBITDA and EBITDA pre																								
EBITDA																								
EBIT	1.043.1	1.049.3	2.092.5	1.047.4	3.139.8	1.038.7	2.086.1	4.178.6	1.173.4	1.177.0	2,350.4	1.234.2	3.584.6	889.6	2.123.7	4,474.2	12.5%	12.2%	12.3%	17.8%	14.2%	-14.4%	1.8%	7.1%
Depreciation and amortization	423.7	422.3	846.1	447.4	1,293.5	474.0	921.4	1.767.5	429.6	532.3	961.9	469.7	1.431.6	598.5	1.068.2	2.030.1	1.4%	26.0%	13.7%	5.0%	10.7%	26.3%	15.9%	14.9%
Regular depreciation and amortization*	217.8	213.5	431.3	229.7	660.9	237.8	467.5	898.8	230.2	233.7	463.9	245.0	708.9	258.9	503.9	967.8	5.7%	9.5%	7.6%	6.7%	7.3%	8.9%	7.8%	7.7%
Impairments not adjusted	0.0	2.1	2.1	0.0	2.1	10.6	10.6	12.7	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2			-100.0%		-100.0%	-97.8%		-98.1%
Amortization of purchased intangible assets	202.8	198.8	401.6	198.9	600.6	202.7	401.6	803.2	196.8	208.7	405.4	213.8	619.2	211.0	424.8	830.2	-3.0%	4.9%	0.9%	7.5%	3.1%	4.1%	5.8%	3.4%
Impairments**	3.2	7.8	11.0	18.9	29.9	202.7	41.7	52.7	2.6	90.0	92.6	10.9	103.5	128.4	139.3	231.9		>1.000%	740.7%					339.9%
Total	1.466.9	1.471.6	2.938.5	1.494.8	4.433.4	1.512.7	3.007.5	5.946.1	1.603.0	1.709.4	3.312.3	1.703.9	5.016.2	1.488.1	3.191.9	6.504.3	9.3%	16.2%	12.7%	14.0%	13.1%	-1.6%	6.1%	9.4%
Adjustments	1,400.9	1,471.0	2,936.5	1,434.0	4,433.4	1,512.7	3,007.5	3,340.1	1,003.0	1,709.4	3,312.3	1,703.9	5,016.2	1,400.1	3, 131.3	0,304.3	9.5%	10.270	12.770	14.0%	15.1/0	-1.0%	0.170	3.470
Acquisition costs	-1.0	-16.8	-17.8	0.0	-17.8	0.0	0.0	-17.8	1.5	8.6	10.1	7.3	17.4	11.6	18.8	28.9	n.m.	n.m.	n m	>1.000%	n m	>1.000%	×1 0000/	n.m.
Restructuring costs	-1.0 27.5	11.6	39.1	22.1	61.2	17.7	39.8	78.9	8.3	37.8	46.1	7.3 63.1	109.2	89.2	152.3	198.4	-69.7%	225.6%	17.9%	185.9%	78.5%	403.9%		151.5%
g .											44.1											8.9%	-0.1%	
Integration costs/IT costs	19.3	17.8	37.1	24.5	61.6	19.0	43.5	80.6	20.0	24.2		22.7	66.9	20.7	43.4	87.5	3.2%	35.9%	18.9%	-7.1%	8.5%			8.6%
Gain (-)/ losses (+) on the divestment of businesses	-6.4	88.4	82.1	5.7	87.8	-91.1	-85.4	-3.3	-10.3	-21.6	-31.9	-4.1	-36.0	-1.5	-5.6	-37.5	61.6%	n.m.	n.m.	n.m.	n.m.	-98.3%	-93.4% >	
Other one-time costs	4.3	3.5	7.8	4.8	12.6	5.9	10.7	18.5	6.2	23.8	30.0	17.5	47.5	20.0	37.5	67.5	45.5%	574.5%	284.4%	267.6%	278.0%			264.6%
Total	43.7	104.6	148.3	57.1	205.4	-48.5	8.6	156.9	25.79	72.6	98.4	106.6	205.0	139.8	246.4	344.9	-41.0%	-30.5%	-33.6%	86.7%	-0.2%			119.8%
EBITDA pre	1,510.6	1,576.2	3,086.8	1,551.9	4,638.7	1,464.2	3,016.1	6,102.9	1,628.8	1,782.0	3,410.8	1,810.5	5,221.2	1,627.9	3,438.4	6,849.1	7.8%	13.1%	10.5%	16.7%	12.6%	11.2%	14.0%	12.2%
b) Reconciliation to EPS pre																								
· ·																								
Reconciliation starting from EBITDA pre	4.540.0	4.570.0	3.086.8	4.554.0	4 000 7	4 404 0	0.040.4	0.400.0	4 000 0	1.782.0	0.440.0	4 040 5	E 004 0	4 007 0	0.400.4	0.040.4	7.00/	42.40/	40.50/	46.70/	42.60/	44 20/	14.0%	42.20/
EBITDA pre	1,510.6	1,576.2	.,	1,551.9	4,638.7	1,464.2	3,016.1	6,102.9	1,628.8	,	3,410.8	1,810.5	5,221.2	1,627.9	3,438.4	6,849.1	7.8%	13.1%	10.5%	16.7%	12.6%	11.2%		12.2%
Regular depreciation and amortization*	-217.8	-213.5	-431.3	-229.7	-660.9	-237.8	-467.5	-898.8	-230.2	-233.7	-463.9	-245.0	-708.9	-258.9	-503.9	-967.8	5.7%	9.5%	7.6%	6.7%	7.3%	8.9%	7.8%	7.7%
Impairments not adjusted	0.0	-2.1	-2.1	0.0	-2.1	-10.6	-10.6	-12.7	0.0	0.0	0.0	0.0	0.0	-0.2	-0.2	-0.2	-100.0%		-100.0%		-100.0%	-97.8%		-98.1%
Financial result	-59.1	-94.8	-153.9	-54.2	-208.0	-46.8	-101.0	-254.9	-34.3	-55.1	-89.4	-47.0	-136.4	-50.5	-97.5	-186.9	-41.9%	-41.9%	-41.9%	-13.2%	-34.4%	7.8%	-3.4%	-26.7%
Adjustments within Financial result	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		40.00/		40 707	45.40/	40.00/	4.5.407	45.00/
Profit before income tax pre	1,233.8	1,265.8	2,499.6	1,268.1	3,767.6	1,168.9	2,437.0	4,936.6	1,364.3	1,493.2	2,857.5	1,518.5	4,375.9	1,318.3	2,836.7	5,694.2	10.6%	18.0%	14.3%	19.7%	16.1%	12.8%		15.3%
Income tax pre	-283.8	-291.1	-574.9	-291.7	-866.6	-268.9	-560.5	-1,135.4	-313.8	-343.4	-657.2	-349.2	-1,006.5	-303.2	-652.5	-1,309.7	10.6%	18.0%	14.3%	19.7%	16.1%	12.8%	16.4%	15.3%
underlying tax rate	23.0%	23.0%	23.0%	23.0%	23.0%	23.0%	23.0%	23.0%	23.0%	23.0%	23.0%	23.0%	23.0%	23.0%	23.0%	23.0%	450.40/	0= 00/	400.00/	=	== +0/		2 22/	
Non-controlling interest	-1.3	-1.6	-2.9	-3.0	-5.9	-4.4	-7.5	-10.4	-3.3	-3.1	-6.4	-2.8	-9.2	-4.4	-7.2	-13.6	152.1%	95.2%	120.9%	-7.4%	55.4%	-1.5%		31.1%
Net income pre	948.7	973.1	1,921.8	973.4	2,895.1	895.7	1,869.1	3,790.8	1,047.2	1,146.7	2,193.8	1,166.4	3,360.3	1,010.7	2,177.1	4,371.0	10.4%	17.8%	14.2%	19.8%	16.1%	12.8%		15.3%
EPS pre in €***	2.18	2.24	4.42	2.24	6.66	2.06	4.30	8.72	2.41	2.64	5.05	2.68	7.73	2.32	5.01	10.05	10.6%	17.9%	14.3%	19.6%	16.1%	12.6%	16.5%	15.3%
2) Reconciliation starting from Profit before tax																								
Profit before income tax	984.1	954.6	1.938.6	993.2	2.931.8	991.9	1.985.1	3.923.7	1.139.1	1.122.0	2.261.0	1.187.2	3.448.2	839.1	2.026.2	4.287.3	15.8%	17.5%	16.6%	19.5%	17.6%	-15.4%	2 1%	9.3%
Amortization of purchased intangible assets	202.8	198.8	401.6	198.9	600.6	202.7	401.6	803.2	1,139.1	208.7	405.4	213.8	619.2	211.0	424.8	830.2	-3.0%	4.9%	0.9%	7.5%	3.1%	4.1%	5.8%	3.4%
												10.9												
Impairments**	3.2	7.8	11.0	18.9	29.9	22.8	41.7	52.7	2.6	90.0	92.6	10.9	103.5	128.4	139.3	231.9	-17.5%	>1.000%	740.7%	-42.1%	246.4%	462.0%	234.0%	339.9%
Adjustments	-1.0	-16.8	-17.8	0.0	17.0	0.0	0.0	17.0	4.5	0.0	10.1	7.0	17.4	11.6	18.8	28.9				-1 0000/		-1 0000/	1 0000/	
Acquisition costs					-17.8		0.0	-17.8	1.5	8.6		7.3		11.6			n.m.	n.m. 225.6%		>1.000%	n.m. : 78.5%	>1.000% : 403.9%		n.m.
Restructuring costs	27.5	11.6	39.1	22.1	61.2	17.7	39.8	78.9	8.3	37.8	46.1	63.1	109.2	89.2	152.3	198.4	-69.7%		17.9%	185.9%				151.5%
Integration costs/IT costs	19.3 -6.4	17.8 88.4	37.1	24.5 5.7	61.6 87.8	19.0 -91.1	43.5	80.6	20.0 -10.3	24.2 -21.6	44.1 -31.9	22.7 -4.1	66.9 -36.0	20.7 -1.5	43.4	87.5 -37.5	3.2% 61.6%	35.9% n.m.	18.9% n.m.	-7.1%	8.5% n.m.	8.9% -98.3%	-0.1% -93.4% >	8.6%
Gain (-)/ losses (+) on the divestment of businesses			82.1				-85.4	-3.3							-5.6			n.m. 574 5%	n.m. 284 4%	n.m.				
Other one-time costs	4.3	3.5	7.8	4.8	12.6	5.9	10.7	18.5	6.2	23.8	30.0	17.5	47.5	20.0	37.5	67.5	45.5%	5/4.5%	284.4%	267.6%	278.0%	236.3%	250.3%	264.6%
Adjustments within Financial result	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		00 50/	22.50/	06 70/	0.00/			
Total adjustments	43.7	104.6	148.3	57.1	205.4	-48.5	8.6	156.9	25.8	72.6	98.4	106.6	205.0	139.8	246.4	344.9	-41.0%	-30.5%	-33.6%	86.7%	-0.2%			119.8%
Profit before income tax pre	1,233.8	1,265.8	2,499.6	1,268.1	3,767.6	1,168.9	2,437.0	4,936.6	1,364.3	1,493.2	2,857.5	1,518.5	4,375.9	1,318.3	2,836.7	5,694.2	10.6%	18.0%	14.3%	19.7%	16.1%	12.8%	16.4%	15.3%
Income tax pre	-283.8	-291.1	-574.9	-291.7	-866.6	-268.9	-560.5	-1,135.4	-313.8	-343.4	-657.2	-349.2	-1,006.5	-303.2	-652.5	-1,309.7	10.6%	18.0%	14.3%	19.7%	16.1%	12.8%	16.4%	15.3%
underlying tax rate	23.0%	23.0% <b>227.9</b>	23.0% 430.0	23.0% <b>212.6</b>	23.0% <b>642.6</b>	23.0% 93.5	23.0% 306.2	23.0% 736.1	23.0% 166.8	23.0% 279.5	23.0% 446.3	23.0% 243.2	23.0% 689.5	23.0% 355.7	23.0% <b>599.0</b>	23.0% 1.045.3	17 50/	22.70/	2.007	14.407	7 201	200 401	05.70/	42.007
Total costs excluded from Net income																	-17.5%	22.7%	3.8%	14.4%	7.3%	280.4%	95.7%	42.0%
Total costs excluded from EPS in €	0.46	0.52	0.99	0.49	1.48	0.22	0.70	1.69	0.38	0.64	1.03	0.56	1.59	0.82	1.38	2.40	-17.4%	23.1%	4.0%	14.3%	7.4%	272.7%	97.1%	42.0%
Non-controlling interest	-1.3 948.7	-1.6	-2.9	-3.0	-5.9	-4.4	-7.5	-10.4	-3.3	-3.1	-6.4	-2.8	-9.2	-4.4	-7.2	-13.6	152.1%	95.2%	120.9%	-7.4%	55.4%	-1.5%		31.1%
Net income pre		973.1 <b>2.24</b>	1,921.8	973.4 <b>2.24</b>	2,895.1	895.7	1,869.1	3,790.8	1,047.2	1,146.7	2,193.8	1,166.4 2.68	3,360.2	1,010.7	2,177.1	4,371.0	10.4%	17.8%	14.2%	19.8%	16.1%	12.8%	16.5%	15.3%
EPS pre in €***	2.18	2.24	4.42	2.24	6.66	2.06	4.30	8.72	2.41	2.64	5.05	2.68	7.73	2.32	5.01	10.05	10.6%	17.9%	14.3%	19.6%	16.1%	12.6%	16.5%	15.3%
Number of theoretical shares in million	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8								

Due to rounding the sum of individual values may not add up to totals presented.

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

\*\* Only reflects impairments classified as adjustments.

<sup>\*\*\*</sup> For continuing operations.

Breakdown of depreciation and amortizat	tion and adju	stments																							
Group					20								202								Change				
€ million	Division	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
-) Di-ti																									
a) Depreciation and amortization  Regular depreciation and amortization*	all	217.8	213.5	431.3	229.7	660.9	237.8	467.5	898.8	230.2	233.7	463.9	245.0	708.9	258.9	503.9	967.8	5.7%	9.5%	7.6%	6.7%	7.3%	8.9%	7.8%	7.7%
Impairments not adjusted	all	0.0	213.5	2.1	0.0	2.1	10.6	10.6	12.7	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	-100.0%	-100.0%	-100.0%		-100.0%	-97.8%	-97.8%	
Amortization of purchased intangible ass		0.0	2.1	2.1	0.0	2.1	10.0	10.0	12.7	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	-100.0%	-100.0%	-100.0%	n.m.	-100.0%	-97.8%	-97.8%	-98.1%
Life Science	LS	110.3	111.6	221.9	108.1	330.1	111.1	219.2	441.2	109.9	121.1	231.0	123.5	354.4	123.5	246.9	477.9	-0.4%	8.4%	4.1%	14.2%	7.4%	11.1%	12.6%	8.3%
Healthcare	HC	11.1	7.0	18.2	7.0	25.2	8.2	15.3	33.4	1.4	1.3	2.8	1.3	4.0	0.3	1.5	4.3	-87.2%	-81.0%	-84.8%	-81.9%	-84.0%	-96.7%	-89.9%	-87.1%
Electronics	EL	81.4	80.2	161.6	83.8	245.3	83.3	167.1	328.6	85.4	86.3	171.7	89.0	260.7	87.3	176.3	348.0	5.0%	7.6%	6.3%	6.3%	6.3%	4.8%	5.5%	5.9%
Total	LL	202.8	198.8	401.6	198.9	600.6	202.7	401.6	803.2	196.8	208.7	405.4	213.8	619.2	211.0	424.8	830.2	-3.0%	4.9%	0.9%	7.5%	3.1%	4.1%	5.8%	3.4%
Impairments**	all	3.2	7.8	11.0	18.9	29.9	22.8	41.7	52.7	2.6	90.0	92.6	10.9	103.5	128.4	139.3	231.9	-17.5%	>1.000%	740.7%	-42.1%	246.4%	462.0%	234.0%	
Total depreciation and amortization	an	423.7	422.3	846.1	447.4	1.293.5	474.0	921.4	1.767.5	429.6	532.3	961.9		1.431.6		1.068.2		1.4%			5.0%		26.3%		
Total depreciation and amortization		423.7	422.3	040.1	447.4	1,293.5	4/4.0	921.4	1,767.5	429.0	532.3	901.9	409.7	1,431.0	590.5	1,000.2	2,030.1	1.4%	26.0%	13.7%	5.0%	10.7%	20.5%	15.9%	14.9%
b) Adjustments																									
Acquisition costs		-1.0	-16.8	-17.8	0.0	-17.8	0.0	0.0	-17.8	1.5	8.6	10.1	7.3	17.4	11.6	18.8	28.9	n.m.	n.m.	n.m.	>1.000%	n.m.	>1.000%	>1.000%	n.m.
Restructuring costs																									
Life Science	LS	7.5	2.4	9.9	9.2	19.0	6.5	15.6	25.5	-3.1	13.1	10.0	28.3	38.2	2.3	30.6	40.6	n.m.	455.4%	1.0%	208.2%	100.8%	-63.7%	95.8%	59.1%
Healthcare	HC	7.3	2.2	9.5	0.1	9.6	1.6	1.6	11.1	1.9	8.3	10.2	24.5	34.7	56.3	80.7	91.0	-73.4%	271.3%	7.6%	>1.000%	262.7%	>1.000%	>1.000%	717.0%
Electronics	EL	8.4	1.5	9.9	8.8	18.7	7.6	16.4	26.3	4.7	8.5	13.1	3.4	16.6	14.0	17.4	30.6	-44.4%	465.9%	33.1%	-61.5%	-11.6%	85.1%	6.1%	16.2%
Corporate and Other	co	4.3	5.5	9.9	4.0	13.9	2.1	6.1	16.0	4.8	7.9	12.8	7.0	19.8	16.5	23.5	36.3	11.4%	43.8%	29.6%	74.3%	42.5%	691.1%	285.4%	127.4%
Total		27.5	11.6	39.1	22.1	61.2	17.7	39.8	78.9	8.3	37.8	46.1	63.1	109.2	89.2	152.3	198.4	-69.7%	225.6%	17.9%	185.9%	78.5%	403.9%	282.9%	151.5%
Integration costs/IT costs																									
Integration Cost	LS/PM/CO	4.9	5.4	10.3	11.1	21.3	9.5	20.6	30.8	5.0	2.2	7.1	-2.1	5.0	4.2	2.1	9.2	2.1%	-60.1%	-30.7%	n.m.	-76.4%	-55.6%	-89.6%	-70.0%
ERP/HR systems	all	14.5	12.4	26.9	13.4	40.3	9.5	22.9	49.8	15.0	22.0	37.0	24.8	61.9	16.4	41.3	78.3	3.6%	77.8%	37.8%	85.0%	53.5%	73.4%	80.2%	57.3%
Total		19.3	17.8	37.1	24.5	61.6	19.0	43.5	80.6	20.0	24.2	44.1	22.7	66.9	20.7	43.4	87.5	3.2%	35.9%	18.9%	-7.1%	8.5%	8.9%	-0.1%	8.6%
Gain (-)/ losses (+) on the divestment of b	ousinesses																								
Costs related to former business activities	CO	-6.3	83.1	76.8	-2.1	74.7	-65.6	-67.7	9.1	-10.3	-11.5	-21.8	-4.1	-25.9	3.2	-0.9	-22.7	62.3%	n.m.	n.m.	92.6%	n.m.	n.m.	-98.7%	n.m.
Costs related to former business activities	EL	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-100.0%	n.m.	-100.0%	n.m.	-100.0%	n.m.	n.m.	-100.0%
Sale of CH, Allergopharma and others	HC	-0.2	5.3	5.1	7.8	12.9	-25.6	-17.7	-12.7	0.0	-10.1	-10.1	0.0	-10.1	-4.7	-4.7	-14.8	-90.0%	n.m.	n.m.	-99.9%	n.m.	-81.6%	-73.5%	17.0%
Costs related to former business activities	LS	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	n.m.	-100.0%	-100.0%
Total		-6.4	88.4	82.1	5.7	87.8	-91.1	-85.4	-3.3	-10.3	-21.6	-31.9	-4.1	-36.0	-1.5	-5.6	-37.5	61.6%	n.m.	n.m.	n.m.	n.m.	-98.3%	-93.4%	>1.000%
Other one-time costs																									
	( HC	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	-100.0%	83.7%	-100.0%	-100.0%	-34.1%
Othera	LS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.							
Others	EL	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.							
	l co	4.3	3.5	7.8	4.8	12.6	5.9	10.7	18.5	6.2	23.8	30.0	17.5	47.5	20.0	37.5	67.5	45.4%	574.5%	284.4%	267.6%	278.0%	236.4%	250.3%	264.7%
Total		4.3	3.5	7.8	4.8	12.6	5.9	10.7	18.5	6.2	23.8	30.0	17.5	47.5	20.0	37.5	67.5	45.5%	574.5%	284.4%	267.6%	278.0%	236.3%	250.3%	264.6%
Total adjustments		43.7	104.6	148.3	57.1	205.4	-48.5	8.6	156.9	25.8	72.6	98.4	106.6	205.0	139.8	246.4	344.9	-41.0%	-30.5%	-33.6%	86.7%	-0.2%	n.m.	>1.000%	119.8%

Due to rounding the sum of individual values may not add up to totals presented.

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

<sup>\*\*</sup> Only reflects impairments classified as adjustments.

Income Statement Merck KGaA, Darmstadt, German	ny																							
Life Science <sup>1</sup> € million	041	00	ual	<b>20</b> Q3	<b>21</b> 9м <b>і</b>	اد		EV.	041	O2	114	<b>20</b> : Q3		04	uol	ΕV	041	ool	H1	Change	e YoY	04	110	<b>5</b> \
€ million	Q1	Q2	H1	Q3	9101	Q4	H2	FY	Q1	Q2	H1	Q3	9101	Q4	H2	FY	Q1	Q2	HI	Q3	9М	Q4	H2	FY
Net sales	2,131.1	2,225.5	4,356.6	2,248.8	6,605.4	2,386.4	4,635.2	8,991.8	2,445.4	2,647.8	5,093.2	2,680.7	7,773.9	2,606.4	5,287.1	10,380.3	14.7%	19.0%	16.9%	19.2%	17.7%	9.2%	14.1%	15.4%
Cost of sales	-849.1	-887.4	-1,736.4	-900.7	-2,637.2	-940.9	-1,841.7	-3,578.1	-965.1	-1,052.3	-2,017.4	-1,070.5	-3,087.9	-1,192.1	-2,262.6	-4,280.0	13.7%	18.6%	16.2%	18.9%	17.1%	26.7%	22.9%	19.6%
thereof amortization of intangible assets	-13.8	-13.9	-27.7	-14.3	-42.0	-11.0	-25.3	-53.0	-13.5	-16.7	-30.2	-15.2	-45.4	-15.1	-30.2	-60.4	-2.2%	20.0%	9.0%	6.4%	8.1%	36.8%	19.6%	14.1%
Gross profit	1,282.0	1,338.1	2,620.1	1,348.1	3,968.3	1,445.4	2,793.5	5,413.7	1,480.4	1,595.5	3,075.8	1,610.2	4,686.0	1,414.4	3,024.5	6,100.4	15.5%	19.2%	17.4%	19.4%	18.1%	-2.1%	8.3%	12.7%
in % of net sales	60.2%	60.1%	60.1%	59.9%	60.1%	60.6%	60.3%	60.2%	60.5%	60.3%	60.4%	60.1%	60.3%	54.3%	57.2%	58.8%								
SG&A	-613.4	-607.3	-1,220.7	-645.9	-1,866.6	-716.8	-1,362.6	-2,583.4	-669.0	-731.6	-1,400.5	-785.3	-2,185.8	-707.4	-1,492.6	-2,893.2	9.1%	20.5%	14.7%	21.6%	17.1%	-1.3%	9.5%	12.0%
in % of net sales	28.8%	27.3%	28.0%	28.7%	28.3%	30.0%	29.4%	28.7%	27.4%	27.6%	27.5%	29.3%	28.1%	27.1%	28.2%	27.9%								
Marketing and selling expenses	-501.0	-505.3	-1,006.3	-528.7	-1,535.1	-584.0	-1,112.8	-2,119.1	-552.0	-608.8	-1,160.8	-633.9	-1,794.7	-605.4	-1,239.2	-2,400.1	10.2%	20.5%	15.4%	19.9%	16.9%	3.7%	11.4%	13.3%
thereof amortization of intangible assets (M&S)	-96.2	-96.1	-192.4	-93.1	-285.4	-99.8	-192.9	-385.3	-95.6	-103.6	-199.2	-107.5	-306.7	-107.7	-215.2	-414.4	-0.6%	7.7%	3.6%	15.5%	7.5%	7.9%	11.6%	7.6%
Administration expenses	-81.6	-92.2	-173.9	-93.2	-267.0	-85.4	-178.6	-352.4	-91.5	-102.8	-194.2	-112.0	-306.2	-93.4	-205.4	-399.7	12.1%	11.4%	11.7%	20.2%	14.7%	9.4%	15.0%	13.4%
Impairment losses and reversals (IFRS 9)	-5.2	-1.3	-6.5	-0.1	-6.6	3.6	3.5	-3.0	-1.7	-7.6	-9.3	1.7	-7.7	-0.9	8.0	-8.5	-67.3%	477.1%	42.9%	n.m.	15.6%	n.m.	-76.7%	181.8%
Other operating expenses/income	-25.6	-8.4	-34.0	-23.9	-57.9	-50.9	-74.8	-108.8	-23.8	-12.3	-36.1	-41.1	-77.2	-7.7	-48.8	-84.9	-6.8%	46.1%	6.3%	72.0%	33.4%	-84.8%	-34.8%	-21.9%
Impairments**	0.0	-0.1	-0.1	0.0	-0.1	-11.0	-11.0	-11.1	-1.3	0.0	-1.3	0.0	-1.3	-23.2	-23.2	-24.5	n.m.	-88.3% >	1.000%	n.m.	>1.000%	111.5%	111.6%	121.1%
Research and development costs	-75.0	-87.0	-162.0	-88.2	-250.2	-100.5	-188.7	-350.7	-88.1	-98.5	-186.7	-105.7	-292.3	-106.8	-212.5	-399.2	17.4%	13.3%	15.2%	19.9%	16.9%	6.3%	12.6%	13.8%
in % of net sales	3.5%	3.9%	3.7%	3.9%	3.8%	4.2%	4.1%	3.9%	3.6%	3.7%	3.7%	3.9%	3.8%	4.1%	4.0%	3.8%								
thereof amortization of intangible assets (R&D)	-0.3	-1.6	-1.9	-0.8	-2.7	-0.3	-1.0	-2.9	-0.8	-0.8	-1.6	-0.8	-2.4	-0.7	-1.5	-3.1	158.4%	-49.8%	-15.9%	1.3%	-10.8%	159.5%	41.3%	4.6%
EBIT	593.5	643.8	1,237.4	614.1	1,851.5	628.2	1,242.3	2,479.7	723.3	765.4	1,488.6	719.2	2,207.9	600.2	1,319.4	2,808.0	21.9%	18.9%	20.3%	17.1%	19.2%	-4.5%	6.2%	13.2%
in % of net sales	27.9%	28.9%	28.4%	27.3%	28.0%	26.3%	26.8%	27.6%	29.6%	28.9%	29.2%	26.8%	28.4%	23.0%	25.0%	27.1%								
Depreciation and amortization	186.0	191.3	377.3	191.9	569.3	208.6	400.5	777.9	198.3	209.9	408.2	216.6	624.9	244.9	461.5	869.7	6.6%	9.7%	8.2%	12.9%	9.8%	17.4%	15.2%	11.8%
EBITDA	779.6	835.2	1,614.7	806.0	2,420.8	836.8	1,642.8	3,257.5	921.6	975.3	1,896.9	935.9	2,832.7	845.0	1,780.9	3,677.8	18.2%	16.8%	17.5%	16.1%	17.0%	1.0%	8.4%	12.9%
in % of net sales	36.6%	37.5%	37.1%	35.8%	36.6%	35.1%	35.4%	36.2%	37.7%	36.8%	37.2%	34.9%	36.4%	32.4%	33.7%	35.4%								
EBITDA pre	793.6	829.1	1,622.7	823.6	2,446.4	840.2	1,663.8	3,286.6	927.1	1,005.7	1,932.8	976.4	2,909.2	850.3	1,826.8	3,759.6	16.8%	21.3%	19.1%	18.6%	18.9%	1.2%	9.8%	14.4%
in % of net sales	37.2%	37.3%	37.2%	36.6%	37.0%	35.2%	35.9%	36.6%	37.9%	38.0%	37.9%	36.4%	37.4%	32.6%	34.6%	36.2%								
Reconciliation to EBITDA pre																								
EBITDA	779.6	835.2	1 614 7	806.0	2.420.8	836.8	1.642.8	3,257.5	921.6	975.3	1.896.9	935.9	2.832.7	845.0	1,780.9	3,677.8	18.2%	16.8%	17.5%	16.1%	17.0%	1.0%	8.4%	12.9%
	119.0	033.2	1,014.7	0.00.0	2,420.0	030.8	1,042.8	3,237.5	921.0	910.3	1,090.9	933.9	2,032.7	040.0	1,700.9	3,077.8	10.2%	10.6%	17.5%	10.1%	17.0%	1.0%	0.4%	12.9%
Adjustments thereof: Cost of Sales	0.6	0.5	1.0	2.9	3.9	0.5	3.4	1.1	0.1	3.0	3.1	2.4	5.5	1.2	3.7	6.7	-87.9%	538.0%	198.7%	-15.2%	41.6%	146.2%	8.9%	53.6%
			1.0					4.4								-								
thereof: Marketing and selling expenses	0.5	0.5	1.0	2.1	3.2	2.3 -3.2	4.5	5.5 21.5	0.1	11.3	11.4	4.8	16.2 26.4	0.3 -4.3	5.1	16.4 22.2		>1.000% >		125.0%	412.2%	-87.9%	13.5%	
thereof: Administration expenses thereof: Other operating expenses/income	7.5	8.0 -15.0	15.5 -9.6	9.3 3.3	24.8 -6.2	-3.2 2.4	6.1 5.8	-3.8	7.2 -1.9	9.0 7.0	16.3 5.0	10.2	28.2		5.9 31.5	36.5	-3.3%	12.9%	5.1%	9.4%	6.7%	31.9%	-2.6%	2.9%
inereor: Other operating expenses/income	5.5	-15.0	-9.6	3.3	-6.2	2.4	5.8	-3.8	-1.9	7.0	5.0	23.1	28.2	8.4	31.5	30.5	n.m.	n.m.	n.m.	600.4%	n.m.	242.8%	448.3%	n.m.

0.1

5.5

0.1

30.4

927.1 1,005.7 1,932.8

0.2

35.9

0.0

40.5

976.4 2,909.2

0.2

76.5 5.29730

-0.3

-0.3

45.8

850.3 1,826.8 3,759.6

-0.1

81.8

n.m.

-60.7%

n.m.

16.8% 21.3% 19.1% 18.6% 18.9%

n.m.

n.m.

n.m. 349.8% 130.5% 199.0% 54.4% 118.0% 181.9%

1.2%

n.m.

9.8% 14.4%

n.m.

Due to rounding the sum of individual values may not add up to totals presented.

thereof: Research and development

Total

EBITDA pre

0.0

14.1

793.6

0.0

-6.1

829.1 1,622.7

0.0

8.0

0.0

17.6

823.6 2,446.4

0.0

25.6

1.4

3.4

1.4

21.0

840.2 1,663.8 3,286.6

29.0

<sup>&</sup>lt;sup>1</sup> Prior-year figures have been adjusted due to product reallocations between the Life Science and Electronics business sectors.

Detailed reconciliation - Life Science <sup>1</sup>																								
				202								202								Change				
€ million	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
EBIT	593.5	643.8	1,237.4	614.1	1,851.5	628.2	1,242.3	2,479.7	723.3	765.4	1,488.6	719.2	2,207.9	600.2	1,319.4	2,808.0	21.9%	18.9%	20.3%	17.1%	19.2%	-4.5%	6.2%	13.2%
Regular depreciation and amortization*	75.7	79.6	155.3	83.8	239.1	86.5	170.4	325.7	87.2	88.8	176.0	93.2	269.2	98.2	191.4	367.4	15.1%	11.6%	13.3%	11.1%	12.6%	13.5%	12.3%	12.8%
Amortization of purchased intangible assets	110.3	111.6	221.9	108.1	330.1	111.1	219.2	441.2	109.9	121.1	231.0	123.5	354.4	123.5	246.9	477.9	-0.4%	8.4%	4.1%	14.2%	7.4%	11.1%	12.6%	8.3%
Impairments**	0.0	0.1	0.1	0.0	0.1	11.0	11.0	11.1	1.3	0.0	1.3	0.0	1.3	23.2	23.2	24.5	n.m.	-88.3%	>1.000%	n.m.	>1.000%	111.5%	111.6%	121.1%
Total depreciation and amortization	186.0	191.3	377.3	191.9	569.3	208.6	400.5	777.9	198.3	209.9	408.2	216.6	624.9	244.9	461.5	869.7	6.6%	9.7%	8.2%	12.9%	9.8%	17.4%	15.2%	11.8%
EBITDA	779.6	835.2	1,614.7	806.0	2,420.8	836.8	1,642.8	3,257.5	921.6	975.3	1,896.9	935.9	2,832.7	845.0	1,780.9	3,677.8	18.2%	16.8%	17.5%	16.1%	17.0%	1.0%	8.4%	12.9%
Adjustments																								
Acquisition costs	-1.1	-16.8	-17.9	0.0	-17.9	0.0	0.0	-17.9	0.5	7.5	8.0	2.2	10.1	7.4	9.5	17.5	n.m.	n.m.	n.m.	>1.000%	n.m.	>1.000%	>1.000%	n.m.
Restructuring costs																								
Restructuring costs	7.5	2.4	9.9	9.2	19.0	6.5	15.6	25.5	-3.1	13.1	10.0	28.3	38.2	2.3	30.6	40.6	n.m.	455.4%	1.0%	208.2%	100.8%	-63.7%	95.8%	59.1%
Total	7.5	2.4	9.9	9.2	19.0	6.5	15.6	25.5	-3.1	13.1	10.0	28.3	38.2	2.3	30.6	40.6	n.m.	455.4%	1.0%	208.2%	100.8%	-63.7%	95.8%	59.1%
Integration costs/IT costs																								
Integration Cost	0.3	1.0	1.2	0.2	1.4	0.4	0.6	1.8	1.0	1.4	2.4	0.3	2.7	1.2	1.6	3.9	239.8%	43.3%	89.8%	69.6%	87.1%	228.8%	175.6%	116.5%
ERP/HR systems	7.2	7.4	14.7	8.2	22.9	-3.4	4.8	19.5	7.1	8.6	15.6	9.8	25.5	-5.7	4.1	19.8	-1.9%	15.0%	6.7%	19.3%	11.2%	66.3%	-14.1%	1.6%
Total	7.5	8.4	15.9	8.4	24.3	-3.0	5.4	21.3	8.1	9.9	18.0	10.1	28.1	-4.4	5.7	23.7	7.6%	18.2%	13.2%	20.5%	15.7%	46.3%	5.8%	11.3%
Gain (-)/ losses (+) on the divestment of busin	nesses																							
Costs related to former business activities	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	n.m.	-100.0%	-100.0%
Total	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	n.m.	-100.0%	-100.0%
Other one-time costs																								
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.							
Total	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.							
Total adjustments	14.1	-6.1	8.0	17.6	25.6	3.4	21.0	29.0	5.5	30.4	35.9	40.5	76.5	5.3	45.8	81.8	-60.7%	n.m.	349.8%	130.5%	199.0%	54.4%	118.0%	181.9%
EBITDA pre	793.6	829.1	1,622.7	823.6	2,446.4	840.2	1,663.8	3,286.6	927.1	1005.7	1,932.8	976.4	2,909.2	850.3	1,826.8	3,759.6	16.8%	21.3%	19.1%	18.6%	18.9%	1.2%	9.8%	14.4%

<sup>\*</sup> Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

<sup>\*\*</sup> Only reflects impairments classified as adjustments.

<sup>&</sup>lt;sup>1</sup> Prior-year figures have been adjusted due to product reallocations between the Life Science and Electronics business sectors.

Income Statement Merck KGaA, Darmstadt, Germany	/																							
Healthcare	1		1	20	21	- 1	1		- 1	1	1		22		1					Chang	e YoY		1	
€ million	Q1	Q2	H1	Q3	9М	Q4	H2	FY	Q1	Q2	H1	Q3	9М	Q4	H2	FY	Q1	Q2	H1	Q3	9М	Q4	H2	FY
Net sales	1,638.9	1,787.7	3,426.7	1,787.6	5,214.2	1,874.6	3,662.2	7,088.9	1,795.0	1,924.2	3,719.1	2,089.3	5,808.5	2,030.3	4,119.6	7,838.7	9.5%	7.6%	8.5%	16.9%	11.4%	8.3%	12.5%	10.6%
Cost of sales	-388.3	-420.2	-808.5	-427.5	-1,236.0	-476.6	-904.1	-1,712.6	-460.7	-483.5	-944.3	-481.3	-1,425.5	-499.4	-980.7	-1,925.0	18.7%	15.1%	16.8%	12.6%	15.3%	4.8%	8.5%	12.4%
thereof amortization of intangible assets	-5.2	-1.1	-6.4	-1.1	-7.5	-1.2	-2.3	-8.7	-1.2	-1.2	-2.4	-1.2	-3.5	-1.3	-2.5	-4.9	-77.4%	2.7%	-63.0%	3.3%	-52.9%	11.7%	7.6%	-44.2%
Gross profit	1,250.6	1,367.6	2,618.2	1,360.0	3,978.2	1,398.0	2,758.1	5,376.2	1,334.2	1,440.7	2,774.9	1,608.1	4,382.9	1,530.8	3,138.9	5,913.8	6.7%	5.3%	6.0%	18.2%	10.2%	9.5%	13.8%	10.0%
in % of net sales	76.3%	76.5%	76.4%	76.1%	76.3%	74.6%	75.3%	75.8%	74.3%	74.9%	74.6%	77.0%	75.5%	75.4%	76.2%	75.4%								
SG&A	-389.4	-452.0	-841.5	-421.0	-1,262.5	-578.9	-1,000.0	-1,841.4	-482.9	-601.3	-1,084.2	-570.7	-1,654.9	-670.0	-1,240.7	-2,324.9	24.0%	33.0%	28.8%	35.6%	31.1%	15.7%	24.1%	26.3%
in % of net sales	23.8%	25.3%	24.6%	23.6%	24.2%	30.9%	27.3%	26.0%	26.9%	31.2%	29.2%	27.3%	28.5%	33.0%	30.1%	29.7%								
Marketing and selling expenses	-370.3	-390.7	-761.1	-386.3	-1,147.4	-452.2	-838.5	-1,599.6	-375.6	-416.9	-792.5	-412.9	-1,205.4	-438.9	-851.8	-1,644.3	1.4%	6.7%	4.1%	6.9%	5.1%	-3.0%	1.6%	2.8%
thereof amortization of intangible assets (M&S)	-4.3	-4.3	-8.6	-4.3	-12.9	-5.5	-9.7	-18.3	-0.2	-0.2	-0.4	-0.1	-0.5	1.1	1.0	0.6	-94.3%	-96.3%	-95.3%	-98.0%	-96.2%	n.m.	n.m.	n.m.
Administration expenses	-72.7	-77.7	-150.5	-78.8	-229.2	-83.9	-162.7	-313.1	-71.2	-81.1	-152.3	-83.5	-235.8	-77.5	-161.0	-313.3	-2.0%	4.3%	1.2%	6.1%	2.9%	-7.7%	-1.0%	0.1%
Impairment losses and reversals (IFRS 9)	-1.7	2.6	0.9	0.5	1.3	3.2	3.6	4.5	-3.7	-0.5	-4.2	4.5	0.3	2.2	6.7	2.5	118.5%	n.m.	n.m.	863.7%	-75.8%	-31.7%	84.0%	-44.9%
Other operating expenses/income	55.3	13.9	69.2	43.6	112.7	-46.0	-2.4	66.8	-32.4	-102.9	-135.3	-78.7	-214.0	-155.8	-234.6	-369.8	n.m.	n.m.	n.m.	n.m.	n.m.	238.9% >	>1.000%	n.m.
Impairments**	0.0	-2.8	-2.8	-0.1	-2.9	-3.0	-3.1	-6.0	-0.8	-89.9	-90.8	-0.5	-91.2	-95.7	-96.2	-187.0	n.m.	>1.000%	>1.000%	389.8%	>1.000%	>1.000% :	>1.000% >	>1.000%
Research and development costs	-416.4	-414.8	-831.2	-485.8	-1,317.0	-395.1	-881.0	-1,712.2	-397.4	-400.7	-798.1	-431.4	-1,229.5	-464.8	-896.2	-1,694.3	-4.6%	-3.4%	-4.0%	-11.2%	-6.6%	17.6%	1.7%	-1.0%
in % of net sales	25.4%	23.2%	24.3%	27.2%	25.3%	21.1%	24.1%	24.2%	22.1%	20.8%	21.5%	20.6%	21.2%	22.9%	21.8%	21.6%								
thereof amortization of intangible assets (R&D)	-1.6	-1.6	-3.2	-1.6	-4.8	-1.6	-3.2	-6.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-100.0%	-100.0%	-100.0%	-100.0%	-100.0%	-97.5%	-98.8%	-99.4%
EBIT	444.7	500.7	945.5	453.2	1,398.6	424.0	877.1	1,822.6	453.9	438.7	892.6	606.0	1,498.5	396.1	1,002.0	1,894.6	2.1%	-12.4%	-5.6%	33.7%	7.1%	-6.6%	14.2%	3.9%
in % of net sales	27.1%	28.0%	27.6%	25.4%	26.8%	22.6%	24.0%	25.7%	25.3%	22.8%	24.0%	29.0%	25.8%	19.5%	24.3%	24.2%								
Depreciation and amortization	78.4	71.6	150.0	78.5	228.5	94.4	172.9	322.9	71.7	164.0	235.7	76.7	312.4	177.9	254.6	490.2	-8.5%	128.9%	57.1%	-2.3%	36.7%	88.4%	47.2%	51.8%
EBITDA	523.1	572.4	1,095.5	531.7	1,627.2	518.4	1,050.0	2,145.5	525.6	602.7	1,128.3	682.6	1,810.9	573.9	1,256.6	2,384.8	0.5%	5.3%	3.0%	28.4%	11.3%	10.7%	19.7%	11.2%
in % of net sales	31.9%	32.0%	32.0%	29.7%	31.2%	27.7%	28.7%	30.3%	29.3%	31.3%	30.3%	32.7%	31.2%	28.3%	30.5%	30.4%								
EBITDA pre	532.9	581.0	1,113.9	540.8	1,654.7	498.4	1,039.2	2,153.1	529.1	603.6	1,132.7	710.9	1,843.5	633.1	1,343.9	2,476.6	-0.7%	3.9%	1.7%	31.4%	11.4%	27.0%	29.3%	15.0%
in % of net sales	32.5%	32.5%	32.5%	30.3%	31.7%	26.6%	28.4%	30.4%	29.5%	31.4%	30.5%	34.0%	31.7%	31.2%	32.6%	31.6%								
Reconciliation to EBITDA pre																								
EBITDA	523.1	572.4	1.095.5	531.7	1.627.2	518.4	1.050.0	2,145.5	525.6	602.7	1.128.3	682.6	1.810.9	573.9	1.256.6	2.384.8	0.5%	5.3%	3.0%	28.4%	11.3%	10.7%	19.7%	11.2%
Adjustments	320.1	2.2	.,200.0		.,	2.0	.,200.0	_, . 10.0	220.0		.,.20.0	202.0	.,	270.0	.,_50.0	2,231.0	0.570	3.370	2.070	231170	,	,,,		/
thereof: Cost of Sales	0.0	-0.4	-0.4	-1.0	-1.4	-1.2	-2.2	-2.6	0.4	1.1	1.5	0.8	2.3	1.3	2.0	3.6	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
thereof: Marketing and selling expenses	5.2	1.7	7.0	0.5	7.4	-0.4	0.0	7.0	0.4	1.4	1.8	1.2	3.1	9.8	11.0	12.9	-92.1%	-17.9%	-73.5%	153.5%	-58.8%	n.m.	>1.000%	83.7%
thereof: Administration expenses	3.4	1.5	4.9	1.6	6.5	5.1	6.7	11.6	2.0	2.9	4.9	4.1	9.0	8.5	12.6	17.5	-42.9%	93.2%	-1.2%		37.5%	68.5%	89.6%	51.0%
thereof: Other operating expenses/income	-0.1	5.2	5.1	8.2	13.3	-26.8	-18.6	-13.6	0.0	-10.1	-10.1	0.0	-10.1	-4.8	-4.8	-14.8	-88.5%	n.m.	n.m.	n.m.	n.m.		-74.4%	9.4%
thereof: Research and development	1.3	0.6	1.9	-0.2	1.7	3.5	3.3	5.1	0.7	5.5	6.3	22.1	28.4	44.3	66.4	72.7	-42.5%	877.3%	236.6%	n.m.	>1.000%			>1.000%
Total	9.8	8.6	18.4	9.1	27.5	-19.9	-10.8	7.6	3.5	0.9	4.4	28.2	32.6	59.1	87.3	91.8	-64.2%	-89.2%	-75.9%		18.6%	n.m.		>1.000%
EBITDA pre	532.9	581.0	1,113.9	540.8	1,654.7	498.4	1,039.2	2,153.1	529.1	603.6	1,132.7	710.9	1,843.5	633.1	1,343.9	2,476.6	-0.7%	3.9%	1.7%	31.4%	11.4%	27.0%	29.3%	15.0%

Detailed reconciliation - Healthcare																							
€ million	Q1	02	H1	202 03	21 aml	04	на	FY	01	02	H1	<b>2022</b> Q3	амІ	04	Hal EV	01	Q2	H1	Change O3	e YoY ам	04	H2	FV
CHIIIIOH	QI	QZ		QU	JIVI	दन	112		QI	QZ		QU	JIVI	47	112 11	QI	QZ		QU	5141	<b>Q</b> 7	1 12	
EBIT	444.7	500.7	945.5	453.2	1,398.6	424.0	877.1	1,822.6	453.9	438.7	892.6	606.0	1,498.5	396.1	1,002.0 1,894.6	2.1%	-12.4%	-5.6%	33.7%	7.1%	-6.6%	14.2%	3.9%
Regular depreciation and amortization*	67.3	59.6	126.9	71.4	198.3	72.5	143.9	270.8	69.5	72.7	142.2	74.9	217.1	81.7	156.6 298.7	3.2%	21.9%	12.0%	5.0%	9.5%	12.6%	8.8%	10.3%
Impairments not adjusted	0.0	2.1	2.1	0.0	2.1	10.6	10.6	12.7	0.0	0.0	0.0	0.0	0.0	0.2	0.2 0.2	-100.0%	-100.0%	-100.0%	n.m.	-100.0%	-97.8%	-97.8%	-98.1%
Amortization of purchased intangible assets	11.1	7.0	18.2	7.0	25.2	8.2	15.3	33.4	1.4	1.3	2.8	1.3	4.0	0.3	1.5 4.3	-87.2%	-81.0%	-84.8%	-81.9%	-84.0%	-96.7%	-89.9%	-87.1%
Impairments**	0.0	2.8	2.8	0.1	2.9	3.0	3.1	6.0	0.8	89.9	90.8	0.5	91.2	95.7	96.2 187.0	n.m.	>1.000%	>1.000%	389.8%	>1.000%	>1.000%	>1.000%	>1.000%
Total depreciation and amortization	78.4	71.6	150.0	78.5	228.5	94.4	172.9	322.9	71.7	164.0	235.7	76.7	312.4	177.9	254.6 490.2	-8.5%	128.9%	57.1%	-2.3%	36.7%	88.4%	47.2%	51.8%
EBITDA	523.1	572.4	1,095.5	531.7	1,627.2	518.4	1,050.0	2,145.5	525.6	602.7	1,128.3	682.6	1,810.9	573.9 °	1,256.6 2,384.8	0.5%	5.3%	3.0%	28.4%	11.3%	10.7%	19.7%	11.2%
Adjustments																							
Acquisition costs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0 0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Restructuring costs																							
Restructuring costs	7.3	2.2	9.5	0.1	9.6	1.6	1.6	11.1	1.9	8.3	10.2	24.5	34.7	56.3	80.7 91.0	-73.4%	271.3%	7.6%	>1.000%	262.7%	>1.000%	>1.000%	717.0%
Total	7.3	2.2	9.5	0.1	9.6	1.6	1.6	11.1	1.9	8.3	10.2	24.5	34.7	56.3	80.7 91.0	-73.4%	271.3%	7.6%	>1.000%	262.7%	>1.000%	>1.000%	717.0%
Integration costs/IT costs																							
Integration Cost	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
ERP/HR systems	2.7	1.1	3.8	1.3	5.1	4.0	5.3	9.1	1.6	2.7	4.3	3.7	8.1	7.6	11.3 15.6	-42.0%	152.5%	13.0%	196.6%	58.6%	87.0%	113.0%	71.2%
Total	2.7	1.1	3.8	1.3	5.1	4.0	5.3	9.1	1.6	2.7	4.3	3.7	8.1	7.6	11.3 15.6	-42.0%	152.5%	13.0%	196.6%	58.6%	87.0%	113.0%	71.2%
Gain (-)/ losses (+) on the divestment of busi	inesses																						
Sale of Kuvan and Biosimilars	-0.5	5.2	4.7	7.8	12.5	1.1	8.9	13.6	0.0	-9.8	-9.8	0.0	-9.8	-4.7	-4.7 -14.4	-100.0%	n.m.	n.m.	-100.0%	n.m.	n.m.	n.m.	n.m.
Sale of Consumer Health	0.2	0.1	0.3	0.0	0.4	-26.7	-26.6	-26.3	0.0	-0.3	-0.4	0.0	-0.3	-0.4	-0.4 -0.7	n.m.	n.m.	n.m.	-58.3%	n.m.	-98.6%	-98.6%	-97.2%
Sale of Allergopharma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	-100.0%	-100.0%	-100.0%	-100.0%	n.m.	-100.0%	-100.0%
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total	-0.2	5.3	5.1	7.8	12.9	-25.6	-17.7	-12.7	0.0	-10.1	-10.1	0.0	-10.1	-4.7	-4.7 -14.8	-90.0%	n.m.	n.m.	-99.9%	n.m.	-81.6%	-73.5%	17.0%
Other one-time costs																							
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	-100.0%	83.7%	-100.0%	-100.0%	-34.1%
Total	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0 0.0	n.m.	n.m.	n.m.	-100.0%	83.7%	-100.0%	-100.0%	-34.1%
Total adjustments	9.8	8.6	18.4	9.1	27.5	-19.9	-10.8	7.6	3.5	0.9	4.4	28.2	32.6	59.1	87.3 91.8	-64.2%	-89.2%	-75.9%	208.6%	18.6%	n.m.	n.m.	>1.000%
EBITDA pre	532.9	581.0	1,113.9	540.8	1,654.7	498.4	1,039.2	2,153.1	529.1	603.6	1,132.7	710.9	1,843.5	633.1	1,343.9 2,476.6	-0.7%	3.9%	1.7%	31.4%	11.4%	27.0%	29.3%	15.0%

<sup>\*</sup> Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments
\*\* Only reflects impairments classified as adjustments.

Income St	atement N	lerck KGaA	, Darmstadt,	Germany
-----------	-----------	------------	--------------	---------

Electronics <sup>1</sup>				20									022						Ċ	hange Yo				
€ million	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Net sales	860.7	856.9	1,717.6	936.3	2,653.9	952.0	1,888.3	3,605.9	957.4	996.4	1,953.9	1,035.7	2,989.5	1,023.7	2,059.3	4,013.2	11.2%	16.3%	13.8%	10.6%	12.6%	7.5%	9.1%	11.3%
Cost of sales	-483.3	-505.5	-988.8	-530.3	-1,519.2	-540.0	-1,070.3	-2,059.2	-560.0	-570.8	-1,130.9	-591.0	-1,721.8	-591.8	-1,182.8	-2,313.7	15.9%	12.9%	14.4%	11.4%	13.3%	9.6%	10.5%	12.4%
thereof amortization of intangible assets	-34.9	-34.0	-68.9	-35.5	-104.4	-35.4	-70.9	-139.8	-35.7	-35.4	-71.0	-35.9	-107.0	-34.9	-70.8	-141.9	2.1%	4.2%	3.1%	1.3%	2.5%	-1.6%	-0.1%	1.5%
Gross profit	377.4	351.4	728.8	406.0	1,134.8	412.0	818.0	1,546.8	397.4	425.6	823.0	444.7	1,267.7	431.8	876.5	1,699.5	5.3%	21.1%	12.9%	9.5%	11.7%	4.8%	7.2%	9.9%
in % of net sales	43.8%	41.0%	42.4%	43.4%	42.8%	43.3%	43.3%	42.9%	41.5%	42.7%	42.1%	42.9%	42.4%	42.2%	42.6%	42.3%								
SG&A	-185.3	-166.5	-351.8	-209.0	-560.8	-199.8	-408.9	-760.7	-176.9	-204.3	-381.2	-222.4	-603.5	-215.2	-437.6	-818.7	-4.5%	22.7%	8.3%	6.4%	7.6%	7.7%	7.0%	7.6%
in % of net sales	21.5%	19.4%	20.5%	22.3%	21.1%	21.0%	21.7%	21.1%	18.5%	20.5%	19.5%	21.5%	20.2%	21.0%	21.2%	20.4%								
Marketing and selling expenses	-135.3	-137.1	-272.4	-146.8	-419.1	-154.1	-300.9	-573.2	-155.7	-163.1	-318.8	-172.6	-491.4	-171.1	-343.6	-662.4	15.1%	19.0%	17.0%	17.6%	17.2%	11.0%	14.2%	15.6%
thereof amortization of intangible assets (M&S)	-45.4	-45.3	-90.6	-47.4	-138.0	-47.0	-94.4	-185.0	-48.9	-50.0	-98.9	-52.3	-151.2	-51.4	-103.7	-202.6	7.7%	10.4%	9.1%	10.3%	9.5%	9.4%	9.9%	9.5%
Administration expenses	-34.4	-29.6	-64.1	-39.0	-103.1	-34.8	-73.8	-137.9	-28.2	-32.9	-61.1	-33.1	-94.2	-33.6	-66.7	-127.9	-18.1%	11.2%	-4.6%	-15.1%	-8.6%	-3.4%	-9.6%	-7.3%
Impairment losses and reversals (IFRS 9)	0.2	-0.4	-0.2	0.2	0.0	-0.9	-0.7	-0.9	0.2	-0.2	0.0	-0.2	-0.2	-0.1	-0.4	-0.3	-2.9%	-44.8%	n.m.	n.m.	>1.000%	-87.9%	-51.9%	-61.8%
Other operating expenses/income	-15.8	0.6	-15.2	-23.4	-38.6	-10.1	-33.5	-48.7	6.8	-8.1	-1.2	-16.5	-17.7	-10.4	-26.9	-28.1	n.m.	n.m.	-91.8%	-29.6%	-54.1%	3.5%	-19.7%	-42.2%
Impairments**	-2.9	-4.5	-7.4	-18.0	-25.4	-7.6	-25.6	-33.0	-0.3	0.0	-0.3	-10.4	-10.7	-9.4	-19.8	-20.1	-90.5%	-99.9%	-96.2%	-42.1%	-57.8%	23.0%	-22.7%	-39.1%
Research and development costs	-66.8	-66.7	-133.5	-71.9	-205.4	-72.4	-144.3	-277.8	-75.3	-72.8	-148.2	-78.4	-226.6	-81.7	-160.1	-308.3	12.7%	9.2%	11.0%	9.1%	10.3%	12.8%	11.0%	11.0%
in % of net sales	7.8%	7.8%	7.8%	7.7%	7.7%	7.6%	7.6%	7.7%	7.9%	7.3%	7.6%	7.6%	7.6%	8.0%	7.8%	7.7%								
thereof amortization of intangible assets (R&D)	-1.1	-1.0	-2.0	-0.9	-2.9	-0.9	-1.8	-3.8	-0.9	-0.9	-1.8	-0.8	-2.6	-1.0	-1.8	-3.6	-18.9%	-3.4%	-11.6%	-11.0%	-11.4%	11.8%	0.2%	-6.1%
EBIT	125.3	118.2	243.5	125.0	368.5	139.8	264.8	508.3	145.2	148.5	293.7	143.9	437.5	134.9	278.8	572.5	15.9%	25.6%	20.6%	15.1%	18.7%	-3.4%	5.3%	12.6%
in % of net sales	14.6%	13.8%	14.2%	13.4%	13.9%	14.7%	14.0%	14.1%	15.2%	14.9%	15.0%	13.9%	14.6%	13.2%	13.5%	14.3%								
Depreciation and amortization	134.2	133.8	268.0	151.5	419.6	141.8	293.4	561.4	133.6	133.6	267.1	150.2	417.3	147.7	297.9	565.1	-0.5%	-0.2%	-0.3%	-0.9%	-0.5%	4.1%	1.5%	0.6%
EBITDA	259.5	252.0	511.5	276.6	788.1	281.6	558.2	1,069.7	278.8	282.0	560.8	294.1	854.9	282.7	576.8	1,137.6	7.4%	11.9%	9.6%	6.3%	8.5%	0.4%	3.3%	6.3%
in % of net sales	30.2%	29.4%	29.8%	29.5%	29.7%	29.6%	29.6%	29.7%	29.1%	28.3%	28.7%	28.4%	28.6%	27.6%	28.0%	28.3%								
EBITDA pre	273.4	257.9	531.3	296.7	828.0	299.7	596.5	1,127.8	289.3	293.1	582.4	301.6	884.0	308.2	609.8	1,192.2	5.8%	13.7%	9.6%	1.6%	6.8%	2.8%	2.2%	5.7%
in % of net sales	31.8%	30.1%	30.9%	31.7%	31.2%	31.5%	31.6%	31.3%	30.2%	29.4%	29.8%	29.1%	29.6%	30.1%	29.6%	29.7%								
Reconciliation to EBITDA pre																								
EBITDA	259.5	252.0	511.5	276.6	788.1	281.6	558.2	1,069.7	278.8	282.0	560.8	294.1	854.9	282.7	576.8	1,137.6	7.4%	11.9%	9.6%	6.3%	8.5%	0.4%	3.3%	6.3%
Adjustments																								
thereof: Cost of Sales	3.8	7.4	11.3	6.9	18.2	5.2	12.1	23.4	1.1	3.7	4.8	2.8	7.6	13.7	16.5	21.3	-71.5%	-50.3%	-57.5%	-59.5%	-58.3%	164.4%	36.5%	-8.9%
thereof: Marketing and selling expenses	0.6	0.6	1.3	1.4	2.6	2.0	3.4	4.6	0.1	1.3	1.4	0.4	1.8	1.2	1.6	2.9	-89.3%	99.5%	7.7%	-71.0%	-33.3%	-40.5%	-52.8%	-36.4%
thereof: Administration expenses	1.7	1.2	2.8	11.0	13.8	1.9	12.8	15.6	0.3	1.9	2.2	1.2	3.4	4.9	6.1	8.3	-81.4%	63.4%	-22.1%	-88.8%	-75.2%	161.3%	-52.5%	-47.0%
thereof: Other operating expenses/income	7.4	-3.8	3.6	0.6	4.2	8.9	9.6	13.1	8.9	3.5	12.4	3.1	15.5	4.7	7.8	20.1	20.0%	n.m.	247.3%	386.8%	268.5%	-47.8%	-18.8%	53.4%
thereof: Research and development	0.4	0.5	0.9	0.3	1.2	0.1	0.4	1.3	0.2	0.7	0.9	0.0	0.9	1.1	1.0	2.0	-46.7%	51.7%	4.2%	n.m.	-21.8%	646.3%	152.3%	51.5%
Total	13.9	5.9	19.8	20.1	39.9	18.1	38.3	58.1	10.6	11.1	21.6	7.5	29.1	25.5	33.0	54.6	-24.2%	88.7%	9.3%	-62.7%	-27.0%	40.7%	-13.7%	-5.9%
EBITDA pre	273.4	257.9	531.3	296.7	828.0	299.7	596.5	1,127.8	289.3	293.1	582.4	301.6	884.0	308.2	609.8	1,192.2	5.8%	13.7%	9.6%	1.6%	6.8%	2.8%	2.2%	5.7%
·																								

<sup>&</sup>lt;sup>1</sup> Prior-year figures have been adjusted due to product reallocations between the Life Science and Electronics business sectors.

Detailed reconciliation - Electronics <sup>1</sup>																								
€ million	Q1	Q2	H1	<b>20</b> Q3	<b>21</b> 9M	Q4	H2	FY	Q1	Q2	H1	<b>202</b> Q3	2 <b>2</b> 9M	Q4	H2	FY	Q1	Q2	H1	Chang Q3	je YoY 9M	Q4	H2	FY
EBIT	125.3	118.2	243.5	125.0	368.5	139.8	264.8	508.3	145.2	148.5	293.7	143.9	437.5	134.9	278.8	572.5	15.9%	25.6%	20.6%	15.1%	18.7%	-3.4%	5.3%	12.6%
Regular depreciation and amortization*	50.0	49.1	99.1	49.8	148.9	50.9	100.7	199.8	47.9	47.3	95.2	50.7	145.9	51.0	101.8	197.0	-4.2%	-3.8%	-4.0%	2.0%	-2.0%	0.3%	1.1%	-1.4%
Amortization of purchased intangible assets	81.4	80.2	161.6	83.8	245.3	83.3	167.1	328.6	85.4	86.3	171.7	89.0	260.7	87.3	176.3	348.0	5.0%	7.6%	6.3%	6.3%	6.3%	4.8%	5.5%	5.9%
Impairments**	2.9	4.5	7.4	18.0	25.4	7.6	25.6	33.0	0.3	0.0	0.3	10.4	10.7	9.4	19.8	20.1	-90.5%	-99.9%	-96.2%	-42.1%	-57.8%	23.0%	-22.7%	-39.1%
Total depreciation and amortization	134.2	133.8	268.0	151.5	419.6	141.8	293.4	561.4	133.6	133.6	267.1	150.2	417.3	147.7	297.9	565.1	-0.5%	-0.2%	-0.3%	-0.9%	-0.5%	4.1%	1.5%	0.6%
EBITDA	259.5	252.0	511.5	276.6	788.1	281.6	558.2	1,069.7	278.8	282.0	560.8	294.1	854.9	282.7	576.8	1,137.6	7.4%	11.9%	9.6%	6.3%	8.5%	0.4%	3.3%	6.3%
A Produced																								
Adjustments	• • •							0.4	4.0							44.4	4 0000/	. 4 0000/	4 0000/	4 0000/	4 0000/		4 0000/	4 0000/
Acquisition costs	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.1	1.0	1.1	2.1	5.1	7.3	4.2	9.3	11.4	>1.000%	>1.000%	>1.000%	>1.000%	>1.000%	n.m.	>1.000%	>1.000%
Restructuring costs																								
Restructuring costs	8.4	1.5	9.9	8.8	18.7	7.6	16.4	26.3	4.7	8.5	13.1	3.4	16.6	14.0	17.4	30.6	-44.4%	465.9%	33.1%	-61.5%	-11.6%	85.1%	6.1%	16.2%
Total	8.4	1.5	9.9	8.8	18.7	7.6	16.4	26.3	4.7	8.5	13.1	3.4	16.6	14.0	17.4	30.6	-44.4%	465.9%	33.1%	-61.5%	-11.6%	85.1%	6.1%	16.2%
Integration costs/IT costs																								
Integration Cost	4.6	4.4	9.0	10.9	19.9	9.1	20.0	29.0	3.9	0.3	4.3	-2.4	1.8	2.9	0.5	4.8	-13.6%	-92.9%	-52.8%	n.m.	-90.9%	-67.8%	-97.5%	-83.6%
ERP/HR systems	0.9	-0.1	0.7	0.4	1.1	1.4	1.8	2.6	0.9	1.1	2.1	1.4	3.5	4.4	5.8	7.9	8.8%	n.m.	179.8%	280.5%	213.7%	204.3%	220.1%	208.4%
Total	5.4	4.3	9.8	11.3	21.0	10.6	21.8	31.6	4.9	1.5	6.3	-1.0	5.3	7.3	6.3	12.6	-10.1%	-66.3%	-35.1%	n.m.	-74.7%	-30.6%	-71.1%	-59.9%
Gain (-)/ losses (+) on the divestment of bus	inesses																							
Costs related to former business activities	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-100.0%	n.m.	-100.0%	n.m.	-100.0%	n.m.	n.m.	-100.0%
Total	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-100.0%	n.m.	-100.0%	n.m.	-100.0%	n.m.	n.m.	-100.0%
Other one-time costs																								
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total adjustments	13.9	5.9	19.8	20.1	39.9	18.1	38.3	58.1	10.6	11.1	21.6	7.5	29.1	25.5	33.0	54.6	-24.2%	88.7%	9.3%	-62.7%	-27.0%	40.7%	-13.7%	-5.9%
EBITDA pre	273.4	257.9	531.3	296.7	828.0	299.7	596.5	1,127.8	289.3	293.1	582.4	301.6	884.0	308.2	609.8	1,192.2	5.8%	13.7%	9.6%	1.6%	6.8%	2.8%	2.2%	5.7%

<sup>\*</sup> Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

<sup>\*\*</sup> Only reflects impairments classified as adjustments.

<sup>&</sup>lt;sup>1</sup> Prior-year figures have been adjusted due to product reallocations between the Life Science and Electronics business sectors.

Income Statement Merck KGaA, Darmstadt, German Corporate and Other <sup>1</sup>				202								20:								Change	e YoY			
€ million	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Net sales	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Cost of sales	0.1	0.1	0.2	-0.2	0.0	-1.3	-1.5	-1.3	-1.2	-2.0	-3.2	-4.7	-7.9	-0.8	-5.5	-8.7	n.m.	n.m.	n.m.	>1.000%	>1.000%	-37.5%	261.4%	562.2%
thereof amortization of intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Gross profit	0.1	0.1	0.2	-0.2	0.0	-1.3	-1.5	-1.3	-1.2	-2.0	-3.2	-4.7	-7.9	-0.8	-5.5	-8.7	n.m.	n.m.	n.m.	>1.000%	>1.000%	-37.5%	261.4%	562.2%
SG&A	-102.5	-190.9	-293.5	-124.1	-417.5	-128.1	-252.1	-545.6	-123.0	-146.0	-269.0	-204.0	-473.1	-200.4	-404.5	-673.5	20.0%	-23.5%	-8.3%	64.4%	13.3%	56.5%	60.4%	23.4%
Marketing and selling expenses	-0.7	-2.3	-3.0	-4.5	-7.4	-4.4	-8.9	-11.8	-4.0	-4.7	-8.7	-4.1	-12.8	5.9	1.8	-7.0	468.1%	109.1%	193.8%	-8.4%	72.2%	n.m.	n.m.	-41.2%
thereof amortization of intangible assets (M&S)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-98.5%	-23.1%	-96.9%	-20.4%	-95.3%	-14.4%	-17.5%	-93.8%
Administration expenses	-82.1	-101.5	-183.6	-94.0	-277.6	-146.2	-240.2	-423.8	-96.3	-113.8	-210.1	-99.3	-309.3	-156.3	-255.6	-465.6	17.3%	12.1%	14.4%	5.6%	11.4%	6.9%	6.4%	9.9%
Impairment losses and reversals (IFRS 9)	0.7	-0.9	-0.2	0.2	0.0	0.8	1.0	0.8	0.2	-0.3	-0.1	0.3	0.2	0.7	1.0	0.9	-68.8%	-64.1%	-44.6%	50.2%	>1.000%	-18.9%	-6.2%	1.8%
Other operating expenses/income	-20.5	-86.2	-106.7	-25.8	-132.5	21.7	-4.1	-110.8	-23.0	-27.2	-50.2	-100.9	-151.1	-50.7	-151.6	-201.8	12.2%	-68.5%	-53.0%	291.8%	14.0%	n.m.	>1.000%	82.1%
Impairments**	-0.3	-0.4	-0.7	-0.8	-1.5	-1.2	-2.0	-2.7	-0.3	0.0	-0.3	0.0	-0.3	-0.1	-0.1	-0.4	-17.6%	-99.1%	-62.8%	-99.6%	-82.0%	-91.9%	-94.9%	-86.5%
Research and development costs	-18.0	-22.6	-40.6	-20.6	-61.2	-23.8	-44.4	-85.1	-24.7	-27.5	-52.2	-26.2	-78.4	-40.4	-66.6	-118.8	37.2%	21.6%	28.5%	26.9%	28.0%	69.6%	49.8%	39.6%
thereof amortization of intangible assets (R&D)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
EBIT	-120.4	-213.5	-333.9	-144.9	-478.8	-153.2	-298.1	-632.0	-148.9	-175.5	-324.4	-234.9	-559.3	-241.6	-476.5	-800.9	23.7%	-17.8%	-2.8%	62.1%	16.8%	57.8%	59.9%	26.7%
Depreciation and amortization	25.1	25.6	50.7	25.5	76.1	29.1	54.5	105.2	25.9	24.9	50.8	26.2	77.0	28.0	54.2	105.1	3.3%	-2.6%	0.3%	2.8%	1.2%	-3.6%	-0.6%	-0.1%
EBITDA	-95.3	-187.9	-283.2	-119.5	-402.7	-124.1	-243.5	-526.8	-123.0	-150.6	-273.6	-208.7	-482.3	-213.6	-422.3	-695.9	29.1%	-19.9%	-3.4%	74.7%	19.8%	72.1%	73.4%	32.1%
EBITDA pre	-89.3	-91.8	-181.1	-109.3	-290.4	-174.2	-283.4	-464.5	-116.8	-120.3	-237.1	-178.4	-415.5	-163.7	-342.0	-579.2	30.7%	31.1%	30.9%	63.3%	43.1%	-6.0%	20.7%	24.7%
Reconciliation to EBITDA pre																								
EBITDA	-95.3	-187.9	-283.2	-119.5	-402.7	-124.1	-243.5	-526.8	-123.0	-150.6	-273.6	-208.7	-482.3	-213.6	-422.3	-695.9	29.1%	-19.9%	-3.4%	74.7%	19.8%	72.1%	73.4%	32.1%
Adjustments																								
thereof: Cost of Sales	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	-8.5%	85.0%	137.2%	99.9%	-18.5%	34.7%	57.9%
thereof: Marketing and selling expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	-100.0%	-100.0%	n.m.
thereof: Administration expenses	7.9	9.4	17.3	7.5	24.8	9.4	16.9	34.2	10.2	15.8	26.0	15.9	41.9	25.2	41.1	67.1	28.7%	68.4%	50.3%	110.7%	68.6%	169.0%	143.0%	96.1%
thereof: Other operating expenses/income	-1.9	86.7	84.8	2.7	87.5	-59.5	-56.8	28.0	-3.9	14.4	10.4	14.5	24.9	24.7	39.2	49.6	104.5%	-83.4%	-87.7%	437.7%	-71.5%	n.m.	n.m.	77.1%
thereof: Research and development	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total	6.0	96.1	102.1	10.2	112.3	-50.1	-39.9	62.2	6.2	30.2	36.4	30.3	66.8	49.9	80.2	116.7	4.1%	-68.6%	-64.3%	196.9%	-40.6%	n.m.	n.m.	87.5%
EDITO 4	20.0	04.0	404.4	400.0	200 4	474.0	200.4	404.5	440.0	400.0	007.4	470.4	445.5	400.7	040.0		20.70/	24.40/	20.00/	62.20/	43 40/	C 00/	00 70/	24 70/

-91.8 -181.1 -109.3 -290.4 -174.2 -283.4 -464.5 -116.8 -120.3 -237.1 -178.4 -415.5 -163.7 -342.0 -579.2

30.7% 31.1% 30.9% 63.3% 43.1% -6.0% 20.7% 24.7%

Due to rounding the sum of individual values may not add up to totals presented.

EBITDA pre

<sup>&</sup>lt;sup>1</sup> Prior-year figures are adjusted due to realignment within Coporate and Other.

Detailed reconciliation -	<ul> <li>Corporate and</li> </ul>	Others
---------------------------	-----------------------------------	--------

				202	1				2022							Change YoY								
€ million	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
EBIT	-120.4	-213.5	-333.9	-144.9	-478.8	-153.2	-298.1	-632.0	-148.9	-175.5	-324.4	-234.9	-559.3	-241.6	-476.5	-800.9	23.7%	-17.8%	-2.8%	62.1%	16.8%	57.8%	59.9%	26.7%
Regular depreciation and amortization*	24.7	25.2	49.9	24.7	74.6	27.9	52.6	102.5	25.7	24.9	50.6	26.2	76.7	28.0	54.1	104.7	3.7%	-1.1%	1.3%	6.0%	2.9%	0.2%	2.9%	2.1%
Amortization of purchased intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-98.5%	-23.1%	-96.9%	-20.4%	-95.3%	-14.4%	-17.5%	-93.8%
Impairments**	0.3	0.4	0.7	0.8	1.5	1.2	2.0	2.7	0.3	0.0	0.3	0.0	0.3	0.1	0.1	0.4	-17.6%	-99.1%	-62.8%	-99.6%	-82.0%	-91.9%	-94.9%	-86.5%
Total depreciation and amortization	25.1	25.6	50.7	25.5	76.1	29.1	54.5	105.2	25.9	24.9	50.8	26.2	77.0	28.0	54.2	105.1	3.3%	-2.6%	0.3%	2.8%	1.2%	-3.6%	-0.6%	-0.1%
EBITDA	-95.3	-187.9	-283.2	-119.5	-402.7	-124.1	-243.5	-526.8	-123.0	-150.6	-273.6	-208.7	-482.3	-213.6	-422.3	-695.9	29.1%	-19.9%	-3.4%	74.7%	19.8%	72.1%	73.4%	32.1%
Adjustments																								
Acquisition costs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.							
Restructuring costs																								
Restructuring costs	4.3	5.5	9.9	4.0	13.9	2.1	6.1	16.0	4.8	7.9	12.8	7.0	19.8	16.5	23.5	36.3	11.4%	43.8%	29.6%	74.3%	42.5%	691.1%	285.4%	127.4%
Total	4.3	5.5	9.9	4.0	13.9	2.1	6.1	16.0	4.8	7.9	12.8	7.0	19.8	16.5	23.5	36.3	11.4%	43.8%	29.6%	74.3%	42.5%	691.1%	285.4%	127.4%
IT project costs																								
Integration Cost	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.5	0.0	0.5	0.0	0.1	0.6								
ERP/HR systems	3.7	4.0	7.6	3.6	11.2	7.4	11.0	18.6	5.4	9.6	15.0	9.8	24.8	10.2	20.0	35.0	47.3%	141.1%	96.1%	176.4%	121.6%	37.3%	82.5%	88.1%
Total	3.7	4.0	7.6	3.6	11.2	7.4	11.0	18.6	5.4	10.1	15.5	9.9	25.4	10.2	20.1	35.6	47.6%	152.9%	102.5%	178.2%	126.5%	37.9%	83.4%	91.2%
Gain (-)/ losses (+) on the divestment of busing	inesses																							
Costs related to former business activities	-6.3	83.1	76.8	-2.1	74.7	-65.6	-67.7	9.1	-10.3	-11.5	-21.8	-4.1	-25.9	3.2	-0.9	-22.7	62.3%	n.m.	n.m.	92.6%	n.m.	n.m.	-98.7%	n.m.
Total	-6.3	83.1	76.8	-2.1	74.7	-65.6	-67.7	9.1	-10.3	-11.5	-21.8	-4.1	-25.9	3.2	-0.9	-22.7	62.3%	n.m.	n.m.	92.6%	n.m.	n.m.	-98.7%	n.m.
Other one-time costs																								
Others	4.3	3.5	7.8	4.8	12.6	5.9	10.7	18.5	6.2	23.8	30.0	17.5	47.5	20.0	37.5	67.5	45.4%	574.5%	284.4%	267.6%	278.0%	236.4%	250.3%	264.7%
Total	4.3	3.5	7.8	4.8	12.6	5.9	10.7	18.5	6.2	23.8	30.0	17.5	47.5	20.0	37.5	67.5	45.4%	574.5%	284.4%	267.6%	278.0%	236.4%	250.3%	264.7%
Total adjustments	6.0	96.1	102.1	10.2	112.3	-50.1	-39.9	62.2	6.2	30.2	36.4	30.3	66.8	49.9	80.2	116.7	4.1%	-68.6%	-64.3%	196.9%	-40.6%	n.m.	n.m.	87.5%
EBITDA pre	-89.3	-91.8	-181.1	-109.3	-290.4	-174.2	-283.4	-464.5	-116.8	-120.3	-237.1	-178.4	-415.5	-163.7	-342.0	-579.2	30.7%	31.1%	30.9%	63.3%	43.1%	-6.0%	20.7%	24.7%

<sup>\*</sup> Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

<sup>\*\*</sup> Only reflects impairments classified as adjustments.

Income Statement Merck KGaA, Darmstadt, Germany Group € million H1 -254.9 -97.5 -186.9 Financial result -59.1 -94.8 -153.9 -54.2 -208.0 -46.8 -101.0 -34.3 -55.1 -89.4 -47.0 -136.4 -50.5 Interest result -64.8 -56.5 -121.3 -44.8 -166.1 -31.6 -76.4 -197.7 -23.0 -48.9 -71.9 -22.3 -94.2 -30.0 -52.4 -124.3 Interest income 6.4 8.0 14.4 11.5 25.9 19.8 31.3 45.8 25.0 7.4 32.4 28.6 60.9 8.4 37.0 69.4 Interest expenses -71.2 -64.4 -135.7 -56.3 -192.0 -51.4 -107.7 -243.4 -48.0 -56.2 -104.3 -50.9 -155.2 -38.5 -89.4 -193.7 Result from financial investments 1.0 5.3 6.3 4.9 13.9 -3.0 -3.7 -6.8 -2.2 -8.9 6.9 4.8 -2.0

2.7

-4.7

0.0

-13.3

7.6

-39.4

-31.8

0.0

-2.5

-5.9

0.1

-7.1

4.7

-0.1

-9.6

-1.1

0.0

-6.4

0.0

-16.1

-16.0

-17.2

0.0

-10.4

-16.9

0.0

-16.9

-33.0

0.0

-26.4

-34.1

-0.1

-18.1

-14.2

0.0

11.2

-34.7

-18.5

0.0

Currency difference - financing

Others

Interest quota - pensions and other provisi

-6.0

10.7

0.0

-15.4

-28.3

0.0

-21.3

-17.5

0.0

-13.4

-0.9

0.0

Q1	02	H1l	Q3		04	H2	FY
~.							
-41.9%	-41.9%	-41.9%	-13.2%	-34.4%	7.8%	-3.4%	-26.7%
-64.5%	-13.4%	-40.7%	-50.2%	-43.3%	-4.8%	-31.4%	-37.1%
289.0%	-7.7%	124.6%	148.6%	135.2%	-57.5%	18.1%	51.6%
-32.6%	-12.7%	-23.1%	-9.6%	-19.2%	-25.2%	-17.0%	-20.4%
n.m.	n.m.	n.m.	n.m.	n.m.	156.7%	-37.2%	n.m.
-59.0%	-53.8%	-55.2%	-51.7%	-53.9%	121.8%	-6.5%	-32.9%
n.m.	n.m.	-93.7%	>1.000%	-6.9%	27.3%	132.1%	7.4%
n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.

Cash Flow Statement Merck KGaA, Darmstadt, Germany																
Group				202								202				
€ million	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Profit after tax	747.9	746.8	1,494.7	763.8	2,258.5	806.6	1,570.4	3,065.0	883.8	870.1	1,754.0	926.0	2,679.9	659.3	1,585.3	3,339.3
Depreciation/amortization/impairment losses/reversals of impairment losses 1	423.7	422.3	846.1	447.4	1,293.5	474.0	921.4	1,767.5	429.6	532.3	961.9	469.7	1,431.6	598.5	1,068.2	2,030.1
of tangible assets	198.1	203.6	401.7	207.6	609.3	231.7	439.3	841.0	206.7	208.8	415.4	219.3	634.7	252.7	472.0	887.4
of intangible assets	225.6	218.7	444.3	239.8	684.2	242.3	482.1	926.5	222.9	323.6	546.5	250.4	796.8	345.8	596.2	1,142.7 -916.7
Changes in working capital Changes in inventories	-88.4 -108.0	-168.0 -116.7	-256.4 -224.7	-81.7 -159.7	-338.1 -384.4	-10.5 -87.2	-92.3 -247.0	-348.7 -471.6	-322.3 -186.4	-324.9 -200.7	-647.2 -387.1	-180.7 -248.6	-827.9 -635.7	-88.8 31.5	-269.5 -217.2	-604.2
Changes in inventories Changes in trade accounts receivable	-108.0 -314.2	-65.3	-224.7	-159.7	-384.4 -433.0	-87.2 122.8	69.3	-471.6	-186.4	-200.7 -193.8	-536.9	-248.6 149.1	-035.7	-25.3	123.8	-604.2 -413.1
Changes in trade accounts receivable Changes in trade accounts payable/ refund liabilities	333.8	13.9	347.7	131.5	479.2	-46.1	85.4	433.1	207.2	69.6	276.8	-81.2	195.6	-25.3 -95.0	-176.1	100.7
Changes in provisions	-33.7	88.3	54.6	191.4	246.1	-50.1	141.3	196.0	21.6	-174.0	-152.4	111.2	-41.2	153.7	264.9	112.5
Changes in other assets and liabilities	160.4	-216.7	-56.3	127.8	71.5	-192.3	-64.6	-120.8	-148.6	-51.5	-200.1	234.5	34.4	-313.2	-78.7	-278.8
Neutralization of gain/loss on disposal of fixed assets and other disposals	-5.8	-17.5	-23.3	-8.3	-31.6	7.8	-0.5	-23.8	-26.8	-12.1	-38.9	-3.7	-42.5	-5.8	-9.4	-48.3
Other non-cash income and expenses <sup>1</sup>	11.9	33.0	44.9	26.3	71.2	9.4	35.7	80.6	2.9	12.2	15.1	-5.3	9.8	11.2	5.9	21.0
Operating Cash Flow	1.216.1	888.2	2,104.3	1.466.7	3.571.0	1,044.7	2.511.4	4.615.7	840.1	852.3	1,692.4	1.551.7	3,244.1	1.015.0	2.566.8	4,259.1
thereof: from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
·																
Payments for investments in intangible assets	-47.1	-21.5	-68.5	-218.5	-287.1	-68.2	-286.8	-355.3	-67.9	-52.0	-119.9	-89.2	-209.2	-66.3	-155.6	-275.5
Payments from the disposal of intangible assets	8.7	21.4	30.2	5.2	35.4	3.8	9.0	39.2	20.6	4.8	25.4	10.1	35.4	2.3	12.4	37.7
Payments for investments in property, plant and equipment	-315.0	-253.9	-568.9	-299.1	-868.0	-197.5	-496.6	-1,065.5	-430.5	-246.0	-676.5	-388.5	-1,065.0	-466.4	-854.9	-1,531.4
Payments from the disposal of property, plant and equipment	6.4	-1.9	4.5	3.9	8.4	-1.8	2.1	6.6	17.1	-7.2	9.9	3.9	13.8	7.1	11.0	20.9
Payments for acquisitions less acquired cash and cash equivalents (net)	0.0	0.0	0.0	-4.2	-4.2	0.0	-4.2	-4.2	-694.8	0.0	-694.8	-0.7	-695.5	-158.2	-159.0	-853.8
Payments from other divestments	0.9	0.3	1.1	0.0	1.2	0.0	0.0	1.2	3.7	0.5	4.2	0.1	4.3	-0.1	0.1	4.2
Payments for investments in financial assets	-10.2	-14.2	-24.4	-146.1	-170.5	-97.8	-244.0 30.0	-268.3	-24.4	-23.2	-47.6	-168.7	-216.3	-148.1	-316.8	-364.4
Proceeds from the disposal of other financial assets	9.9	28.8 0.0	38.7 0.0	20.6 0.0	59.3 0.0	9.4 0.0	0.0	68.8 0.0	86.8 -100.0	37.5 -500.0	124.3 -600.0	11.2 0.0	135.6 -600.0	83.9 0.0	95.2 0.0	219.5 -600.0
Payments for the acquisition of non-financial assets Proceeds from the disposal of non-financial assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	100.0	0.0	100.0	0.0	100.0	500.0	500.0	600.0
Investing Cash Flow	-346.3	-241.0	-587.3	-638.2	-1.225.6	-352.2	-990.4	-1,577.8	-1.089.4	-78 <b>5.7</b>	-1.875.1	-621.9	-2.496.9	-245.8	-867.6	-2.742.7
thereof: from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
alcicol. Iron discontinuca operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Dividend payments to Merck KGaA shareholders	0.0	-180.9	-180.9	0.0	-180.9	0.0	0.0	-180.9	0.0	-239.1	-239.1	0.0	-239.1	0.0	0.0	-239.1
Dividend payments to non-controlling interests	-7.3	-0.2	-7.4	-0.4	-7.8	-0.6	-1.0	-8.4	-9.6	-1.6	-11.2	0.0	-11.2	-0.3	-0.3	-11.5
Profit withdrawal by E.Merck KG	-48.2	-519.1	-567.3	0.0	-567.3	0.0	0.0	-567.3	-90.5	-625.6	-716.1	0.0	-716.1	0.0	0.0	-716.1
Changes in financial liabilities to E.Merck KG	-25.3	471.0	445.7	-175.0	270.7	-191.9	-366.9	78.8	-406.0	976.7	570.7	-104.7	466.0	-442.7	-547.4	23.3
Other changes in net equity	0.0	0.0	-0.1	-0.1	-0.1	0.0	-0.1	-0.1	0.3	-0.3	0.0	-0.1	-0.2	0.2	0.1	0.1
Changes in current and non-current financial liabilities	86.5	-830.1	-743.6	-955.4	-1,699.0	-126.6	-1,082.0	-1,825.6	190.9	57.1	247.9	-804.4	-556.4	-55.3	-859.7	-611.7
Other changes from financing activities Financing Cash Flow	0.1 <b>5.7</b>	-0.1 <b>-1.059.4</b>	-0.1 <b>-1,053.7</b>	0.0	0.0	0.0 <b>-319.1</b>	0.1 - <b>1.449.9</b>	0.0 <b>-2.503.5</b>	0.0 <b>-315.0</b>	0.1 <b>167.2</b>	0.0 <b>-147.8</b>	0.1 <b>-909.1</b>	0.1 <b>-1.056.9</b>	0.0 <b>-498.1</b>	0.0 <b>-1,407.2</b>	0.1 <b>-1,555.0</b>
thereof: from discontinued operations	0.0	-1,059.4 0.0	-1,053.7	<b>-1,130.8</b> 0.0	-2,184.5	-319.1	-1,449.9	-2,503.5	-315.0	0.0	-147.8 0.0	-909.1 0.0	-1,056.9	-498.1 0.0	-1,407.2	-1,555.0
thereor: from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Changes in cash and cash equivalents	875.4	-412.2	463.3	-302.3	160.9	373.5	71.2	534.4	-564.3	233.8	-330.5	20.8	-309.7	271.1	291.9	-38.6
Changes in cash and cash equivalents due to currency translation	6.8	-0.5	6.3	0.6	6.9	2.5	3.1	9.4	3.5	7.3	10.8	4.1	14.9	-21.7	-17.7	-6.9
Cash and cash equivalents as of January 1st	1,355.4	0.0	1,355.4	0.0	1,355.4	0.0	0.0	1,355.4	1,899.3	0.0	1,899.3	0.0	1,899.3	0.0	0.0	1,899.3
Cash and cash equivalents	2,237.7	-412.7	1,825.0	-301.7	1,523.3	376.0	74.3	1,899.3	1,338.5	241.0	1,579.6	24.9	1,604.4	249.4	274.2	1,853.8
Changes in cash and cash equivalents due to change in scope of consolidation	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Due to rounding the si	um of individual valu	es may not add up	to totals presented.

Due to rounding the sum of individual values may not add up to totals presented.

¹ Prior-year figures have been adjusted due to product reallocations between the Life Science and Electronics business sectors.

			Change				
Q1	Q2	H1	Q3	9M	Q4	H2	FY
18.2%	16.5%	17.3%	21.2%	18.7%	-18.3%	1.0%	8.9%
1.4%	26.0%	13.7%	5.0%	10.7%	26.3%	15.9%	14.9%
4.3%	2.5%	3.4%	5.6%	4.2%	9.1%	7.5%	5.5%
-1.2%	47.9%	23.0%	4.4%	16.5%	42.7%	23.7%	23.3%
264.7%	93.4%	152.4%	121.0%	144.8%	744.1%	192.0%	162.9%
72.6%	72.0%	72.3%	55.6%	65.4%	n.m.	-12.1%	28.1%
9.2%	197.0%	41.5%	n.m.	-10.4%	n.m.	78.7%	33.2%
-37.9%	400.0%	-20.4%	n.m.	-59.2%	106.0%	n.m.	-76.8%
n.m.	n.m.	n.m.	-41.9%	n.m.	n.m.	87.4%	-42.6%
n.m.	-76.2%	255.5%	83.5%	-51.8%	62.9%	22.0%	130.7%
362.4%	-30.9%	66.9%	-55.8%	34.7%	n.m.	>1.000%	102.9%
-76.1%	-63.0%	-66.5%	n.m.	-86.3%	19.7%	-83.3%	-73.9%
-30.9%	-4.1%	-19.6%	5.8%	-9.2%	-2.8%	2.2%	-7.7%
n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
44.3%	142.2%	74.9%	-59.2%	-27.1%	-2.8%	-45.8%	-22.5%
135.7%	-77.6%	-15.9%	92.6%	0.1%	-39.2%	37.0%	-3.7%
36.7%	-3.1%	18.9%	29.9%	22.7%	136.1%	72.1%	43.7%
166.4%	272.1%	121.1%	-0.3%	64.6%	n.m.	430.3%	218.7%
>1.00.4%	0.5%	>1.000%	-82.7%	>1.000%	n.m.	>1.000%	>1.000%
317.6%	80.2%	265.4%	298.4%	266.4%	143.9%	646.4%	269.0%
140.2%	63.4%	95.4%	15.4%	26.9%	51.4%	29.9%	35.8%
777.5%	29.9%	220.9%	-45.4%	128.5%	789.8%	217.1%	219.2%
n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
214.6%	225.9%	219.2%	-2.6%	103.7%	-30.2%	-12.4%	73.8%
n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
n.m.	32.1%	32.1%	n.m.	32.1%	n.m.	n.m.	32.1%
32.2%	877.7%	50.7%	-100.0%	42.6%	-50.1%	-71.8%	36.5%
87.7%	20.5%	26.2%	n.m.	26.2%	n.m.	n.m.	26.2%
>1.000%	107.4%	28.1%	-40.2%	72.1%	130.7%	49.2%	-70.4%
n.m.	>1.000%	-13.5%	54.7%	24.6%	n.m.	n.m.	n.m.
120.7%	n.m.	n.m.	-15.8%	-67.2%	-56.3%	-20.5%	-66.5%
n.m.	n.m.	n.m.	69.2%	n.m.	n.m.	-82.0%	181.7%
n.m.	n.m.	-86.0%	-19.6%	-51.6%	56.1%	-2.9%	-37.9%
n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
n.m.	n.m.	n.m.	n.m.	n.m.	-27.4%	310.2%	n.m.
-48.4%	n.m.	71.2%	545.4%	114.5%	n.m.	n.m.	n.m.
40.1%	n.m.	40.1%	n.m.	40.1%	n.m.	n.m.	40.1%
-40.2%	n.m.	-13.4%	n.m.	5.3%	-33.7%	269.2%	-2.4%
		. 3.470		3.0 /0	- 3 /0		2.470

Balance Sheet Merck KGaA, Darmstadt, Germany																
Group	04.14	202		04 5	04.14	20:		04.5	04.14	Shares of		04 5	04.14		s of Totals	0.4 5
€ million Non-current assets	31.Mrz <b>33,273.0</b>	30.Jun <b>32,963.4</b>	30.Sep	31. Dez <b>34,380.3</b>	31.Mrz <b>35,149.3</b>	30.Jun 36,301.2	30.Sep	31.Dez <b>36,325.2</b>	31.Mi		30.Sep 76.5%	31. Dez 75.8%	31.Mrz 76.0%	30.Jun 74.5%	30.Sep	31.Dez 74.9%
Goodwill	16,540.8	16,346.8	16,669.6	17,004.5	17,760.8	18,573.4	19,534.1	3 <b>6,325.2</b> 18,414.7	75.8° 37.7°		38.0%	37.5%	38.4%	38.1%	74.6% 38.4%	74.9% 37.9%
Other intangible assets	7,764.6	7,612.6	7,628.0	7,612.4	7,549.5	7,861.8	8,079.8	7,301.8	17.79		17.4%	16.8%	16.3%	16.1%	15.9%	15.0%
Property, plant and equipment	6,551.6	6,601.4	6,761.3	7,217.0	7,302.9	7,573.4	7,945.6	8,203.0	14.99		15.4%	15.9%	15.8%	15.5%	15.6%	16.9%
Investments accounted for using the equity method	2.1	2.1	2.2	2.8	2.8	3.0	3.1	2.9	0.0	6 0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Other non-current financial assets	768.1	742.5	792.2	911.2	902.3	901.9	961.7	957.1	1.89		1.8%	2.0%	2.0%	1.9%	1.9%	2.0%
Other non-current receivables	27.8	28.6	28.5	25.4	24.5	25.7	28.1	27.1	0.19		0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
Other non-current non-financial assets	84.7	87.4	85.0	94.8	104.8	99.5	104.1	99.1	0.29		0.2%	0.2%	0.2%	0.2%	0.2%	0.2%
Non-current income tax receivables	10.0	9.9	9.7	9.8	9.8	9.7	9.4	9.8	0.09		0.0%	0.0%	0.0%	0.0% 2.6%	0.0%	0.0%
Deferred tax assets	1,523.3	1,532.2	1,544.8	1,502.5	1,492.0	1,252.9	1,324.0	1,309.6	3.59	6 3.6%	3.5%	3.3%	3.2%	2.6%	2.6%	2.7%
Current assets	10,617.5	10,181.8	10,315.1	10,982.0	11,085.3	12,415.9	12,943.1	12,200.9	24.20		23.5%	24.2%	24.0%	25.5%	25.4%	25.1%
Inventories	3,462.4	3,563.9	3,759.9	3,900.5	4,142.8	4,473.7	4,859.9	4,632.1	7.99		8.6%	8.6%	9.0%	9.2%	9.5%	9.5%
Trade and other current receivables	3,654.1	3,656.6	3,752.5	3,646.1	4,138.4	4,413.7	4,346.3 137.2	4,113.6	8.39 0.49		8.6%	8.0% 0.5%	9.0% 0.4%	9.1% 0.3%	8.5% 0.3%	8.5% 0.3%
Contract assets Other current financial assets	162.3 60.3	114.2 44.8	176.9 141.7	206.7 174.0	207.0 105.9	156.1 133.5	347.1	128.4 321.3	0.4		0.4% 0.3%	0.5%	0.4%	0.3%	0.3%	0.3%
Other current non-financial assets	631.1	624.5	683.5	663.3	792.8	1,362.5	1,335.0	705.4	1.49		1.6%	1.5%	1.7%	2.8%	2.6%	1.5%
Current income tax receivables	409.6	352.9	277.4	492.1	359.9	297.0	313.2	446.3	0.99		0.6%	1.1%	0.8%	0.6%	0.6%	0.9%
Cash and cash equivalents	2,237.7	1,825.0	1,523.3	1,899.3	1,338.5	1,579.6	1,604.4	1,853.8	5.19		3.5%	4.2%	2.9%	3.2%	3.2%	3.8%
Assets held for sale	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Total assets	43,890.5	43,145.2	43,836.4	45,362.3	46,234.6	48,717.2	50,933.1	48,526.1	100.0	6 100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Total equity	18,982.6	19,361.3	20,679.1	21,415.6	22,990.1	26,028.7	28,337.0	26,005.4	43.29	6 44.9%	47.2%	47.2%	49.7%	53.4%	55.6%	53.6%
Equity capital	565.2	565.2	565.2	565.2	565.2	565.2	565.2	565.2	1.39	6 1.3%	1.3%	1.2%	1.2%	1.2%	1.1%	1.2%
Capital reserves	3,813.7	3,813.7	3,813.7	3,813.7	3,813.7	3,813.7	3,813.7	3,813.7	8.79		8.7%	8.4%	8.2%	7.8%	7.5%	7.9%
Retained earnings	13,511.1	14,134.1	14,955.3	15,134.5	16,450.0	18,014.6	18,825.1	18,462.9	30.89		34.1%	33.4%	35.6%	37.0%	37.0%	38.0%
Gain/losses recognized in equity	1,025.8	780.3	1,273.2	1,824.5	2,090.5	3,561.4	5,056.3	3,085.6	2.39		2.9%	4.0%	4.5%	7.3%	9.9%	6.4%
Non-controlling interest	66.7	68.1	71.8	77.8	70.7	73.7	76.7	78.0	0.29	6 0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%
Non-current liabilities	14,255.4	13,964.4	13,364.1	13,514.6	13,037.5	12,970.7	13,184.4	13,007.2	32.5		30.5%	29.8%	28.2%	26.6%	25.9%	26.8%
Non-current provisions for employee benefits	3,395.3 274.7	3,350.1	3,388.0	3,401.8	2,879.1	1,666.1	1,954.9	2,030.0 299.4	7.7 <sup>9</sup> 0.6 <sup>9</sup>		7.7% 0.6%	7.5% 0.6%	6.2% 0.6%	3.4% 0.5%	3.8% 0.6%	4.2% 0.6%
Other non-current provisions Non-current financial debt	9.000.8	350.9 8,720.7	270.1 8,194.9	269.3 8,269.7	279.1 8.285.8	265.2 9,385.4	300.3 9,265.6	299.4 9.200.4	20.5		18.7%	18.2%	17.9%	19.3%	0.6% 18.2%	0.6% 19.0%
Other non-current financial liabilities	62.1	67.8	79.0	105.8	148.8	154.8	156.3	146.7	0.19		0.2%	0.2%	0.3%	0.3%	0.3%	0.3%
Other non-current non-financial liabilities	39.5	30.5	15.1	14.8	14.8	15.8	17.0	14.1	0.19		0.2%	0.2%	0.0%	0.0%	0.0%	0.0%
Non-current income tax liabilities	43.3	43.2	43.5	41.7	40.7	41.3	40.9	38.1	0.19		0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
Deferred tax liabilities	1,439.7	1,401.2	1,373.6	1,411.4	1,389.2	1,442.1	1,449.4	1,278.5	3.39	6 3.2%	3.1%	3.1%	3.0%	3.0%	2.8%	2.6%
Current liabilities	10.652.5	9.819.6	9.793.3	10,432.2	10.206.9	9.717.8	9,411.8	9.513.5	24.3	6 22.8%	22.3%	23.0%	22.1%	19.9%	18.5%	19.6%
Current provisions for employee benefits	117.9	144.1	191.3	223.6	174.5	181.8	207.4	238.5	0.39		0.4%	0.5%	0.4%	0.4%	0.4%	0.5%
Other current provisions	419.3	382.2	518.4	377.3	372.0	341.5	355.0	372.4	1.0		1.2%	0.8%	0.8%	0.7%	0.7%	0.8%
Current financial debt	3,346.5	3,277.7	2,769.7	2,531.4	2,344.9	2,417.7	1,784.5	1,227.9	7.69	6 7.6%	6.3%	5.6%	5.1%	5.0%	3.5%	2.5%
Other current financial liabilities	950.1	392.2	372.1	1,191.8	1,076.9	593.6	626.8	1,274.5	2.29		0.8%	2.6%	2.3%	1.2%	1.2%	2.6%
Trade and other current payables	1,936.8	2,106.7	2,131.6	2,380.2	2,356.3	2,456.3	2,445.1	2,497.9	4.49		4.9%	5.2%	5.1%	5.0%	4.8%	5.1%
Refund liabilities	774.6	746.5	739.4	838.9	873.2	972.1	968.1	912.3	1.89		1.7%	1.8%	1.9%	2.0%	1.9% 3.0%	1.9%
Current income tax liabilities	1,603.9	1,464.9	1,570.9	1,420.7	1,465.8	1,430.0	1,520.2	1,483.4	3.79		3.6%	3.1%	3.2%	2.9%		3.1%
Other current non-financial liabilities Liabilities included in disposal groups classified as he	1,503.3 0.0	1,305.2 0.0	1,499.9 0.0	1,468.3 0.0	1,543.4 0.0	1,324.7 0.0	1,504.7 0.0	1,506.5 0.0	3.4° 0.0°		3.4% 0.0%	3.2% 0.0%	3.3% 0.0%	2.7% 0.0%	3.0% 0.0%	3.1% 0.0%
Total liabilities and stockholders' equity	43,890.5	43,145.2	43,836.4	45,362.3	46,234.6	48,717.2	50,933.1	48,526.1	100.0			100.0%	100.0%	100.0%	100.0%	100.0%
Total numinies and stockholders equity	40,000.0	70,170.2	-0,000.4	70,002.0	70,207.0	70,111.2	00,300.1	70,020.1	100.0	. 100.070	100.070	100.070	100.070	100.070	100.070	100.070
1		202				20:				Shares o	f Totals				s of Totals	
	31.Mrz	30.Jun	30.Sep	31. Dez	31.Mrz	30.Jun	30.Sep	31.Dez	31.Mi		30.Sep	31. Dez	31.Mrz	30.Jun	30.Sep	31.Dez
Financial debt	12,347.4	11,998.4	10,964.5	10,801.1	10,630.7	11,803.1	11,050.0	10,428.3	28.19		25.0%	23.8%	23.0%	24.2%	21.7%	21.5%
Net financial debt	10,080.6 207.5	10,140.7 461.5	9,320.2 760.5	8,753.0 1,284.9	9,228.4 209.1	10,165.2 488.0	9,214.6 858.3	8,327.6 1,526.9	23.0° n.n		21.3%	19.3%	20.0%	20.9%	18.1% n.m.	17.2% n.m.
Gross additions to property, plant and equipment (excl.	201.5	401.5	700.5	1,264.9	209.1	400.0	858.3	1,526.9	n.n	ı. rı.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.

Due to rounding the sum of individual values may not add up to totals presented. 

<sup>1</sup> Figures are year-to-date figures from January 1st until stated end date.